

Generation of complex bone marrow organoids from human induced pluripotent stem cells

Received: 17 January 2023

Accepted: 9 January 2024

Published online: 19 February 2024

 Check for updates

Stephanie Frenz-Wiessner¹, Savannah D. Fairley^{1,2}, Maximilian Buser³, Isabel Goek¹, Kirill Salewskij^{4,5}, Gustav Jonsson^{4,5}, David Illig¹, Benedicta zu Putlitz¹, Daniel Petersheim¹, Yue Li¹, Pin-Hsuan Chen¹, Martina Kalauz¹, Raffaele Conca¹, Michael Sterr^{6,7,8}, Johanna Geuder⁹, Yoko Mizoguchi¹⁰, Remco T. A. Megens^{2,11,12}, Monika I. Linder¹, Daniel Kotlarz¹, Martina Rudelius¹³, Josef M. Penninger^{4,14,15,16}, Carsten Marr³ & Christoph Klein^{1,17} 

The human bone marrow (BM) niche sustains hematopoiesis throughout life. We present a method for generating complex BM-like organoids (BMOs) from human induced pluripotent stem cells (iPSCs). BMOs consist of key cell types that self-organize into spatially defined three-dimensional structures mimicking cellular, structural and molecular characteristics of the hematopoietic microenvironment. Functional properties of BMOs include the presence of an in vivo-like vascular network, the presence of multipotent mesenchymal stem/progenitor cells, the support of neutrophil differentiation and responsiveness to inflammatory stimuli. Single-cell RNA sequencing revealed a heterocellular composition including the presence of a hematopoietic stem/progenitor (HSPC) cluster expressing genes of fetal HSCs. BMO-derived HSPCs also exhibited lymphoid potential and a subset demonstrated transient engraftment potential upon xenotransplantation in mice. We show that the BMOs could enable the modeling of hematopoietic developmental aspects and inborn errors of hematopoiesis, as shown for human VPS45 deficiency. Thus, iPSC-derived BMOs serve as a physiologically relevant in vitro model of the human BM microenvironment to study hematopoietic development and BM diseases.

Human hematopoiesis in the BM is a tightly regulated process permitting continuous differentiation of hematopoietic stem cells (HSCs) into mature blood cells, while maintaining an HSC pool through self-renewal¹. Vascular and mesenchymal cells constitute the surrounding BM niche regulating hematopoiesis throughout life². The processes of vasculogenesis, osteogenesis and, subsequently, hematopoiesis are tightly coupled in the fetal BM³. Genetic mutations of BM niche

cells have been shown to be sufficient to induce myelodysplasia or leukemia^{4,5}, emphasizing their critical role not only in development, but also in disease evolution. Murine models of the BM niche have been widely studied^{4–7}, but are limited due to species-specific differences in hematopoiesis⁸. Recently, methods for generating induced pluripotent stem cell (iPSC)-derived hematopoietic organoids⁹ and a first BMO model¹⁰ have been developed. Here, we report an advanced in vitro

A full list of affiliations appears at the end of the paper. ✉ e-mail: christoph.klein@med.uni-muenchen.de

model of the human BM microenvironment that can recapitulate key functional and structural features of the human BM hematopoietic niche with high fidelity.

Results

Development of human BMOs

We devised a feeder- and serum-free protocol of stepwise mesodermal progenitor differentiation through hemogenic endothelium from iPSCs^{11–15} to generate a complex organoid consisting of hematopoietic, mesenchymal and endothelial cells (ECs) within 3 weeks (Fig. 1a). After embryoid body (EB) formation (day –3), mesoderm was induced by the Wnt agonist CHIR99021, bone morphogenetic protein 4 (BMP4) and vascular endothelial growth factor (VEGF) (day 0). Subsequently, mesoderm patterning and hemogenic endothelium (HE) induction was achieved using the activin/nodal pathway inhibitor SB431542, basic fibroblast growth factor (bFGF), stem cell factor (SCF) and VEGF (day 2). To promote organoid self-assembly, we adapted the embedding method of iPSC-derived blood vessel organoids in a collagen I/matrigel matrix^{16,17}. Patterned EBs were embedded into this matrix on day 4 and stimulated with defined cytokines to generate hematopoietic progenitor cells while maintaining EC generation (Fig. 1a). To enhance vascular structure formation^{16,17}, we added a low dose of VEGF from day 8 onwards. On day 10 of differentiation, sprouted EBs (Fig. 1b) were separated and transferred into single wells of an ultra-low-attachment 96-well plate to promote organoid maturation. To evaluate intrinsic emergence of mature lineages, we did not include lineage-directing cytokines. On day 17, the organoids assembled into a spherical shape (Fig. 1b) with a mean diameter of 1,300 μm (range 1,208–1,396 μm , 95% confidence interval (CI) of mean; Extended Data Fig. 1e).

Heterogenous cell type composition

To examine the presence of essential cell types of human BM, we analyzed dissociated BMOs at day 17 of differentiation by flow cytometry (Fig. 1c). To visualize subset heterogeneity, we performed dimensionality reduction of flow cytometric data by *t*-distributed stochastic neighbor embedding (*t*-SNE)¹⁸ (Fig. 1c). We integrated data from three independent differentiations into a joint *t*-SNE visualization, generating a representative map across experiments (Fig. 1c and Supplementary Fig. 1b). Overlay of manually gated populations (Extended Data Fig. 1a and Supplementary Fig. 1a) revealed three main cell clusters (Fig. 1d). Based on CD45 as a panleukocyte marker, CD31 (PECAM1) as a marker for vascular ECs and CD271 (NGFR) as marker for mesenchymal cells, these clusters were assigned as endothelial (CD45⁺CD31⁺), hematopoietic (CD45⁺) and mesenchymal stromal cell clusters (CD45⁺CD31⁺CD271⁺), respectively. Hematopoietic cells were further defined as HSPCs (CD45⁺CD11b⁺CD34⁺) and myeloid cells (CD45⁺CD11b⁺). CD45⁺CD31⁺CD271⁺CD90⁺CD105⁺CD73⁺ cells were characterized as mesenchymal stem/progenitor cells (MSPCs) according to the minimal criteria for multipotent MSPCs¹⁹ (Fig. 1d and Extended Data Fig. 1a). Quantitative analysis of the cellular composition on day 17 of culture yielded an average content of 39.3% hematopoietic cells, 41.3% mesenchymal cells, 6.0% ECs, 1.42% HSPCs and 0.96% MSPCs per BMO ($n = 5$; Fig. 1e). This relative cell type composition was constant at days 17–24 of differentiation (Extended Data Fig. 1b,c). Although each subset was still detectable up to day 60 of differentiation, the frequency of CD45⁺ cells declined over time (Extended Data Fig. 1b,c and Supplementary Fig. 1d–g). (See Supplementary Note and Supplementary Fig. 2 describing our strategies to determine reproducibility of the protocol using iPSC lines 2–5.) To validate the immunophenotypic subsets morphologically, we sorted distinct subsets using fluorescence-activated cell sorting (FACS) (Fig. 1f,g,h). Giemsa-stained cytopins of isolated HSPCs (CD45⁺CD11b⁺CD34⁺) and myeloid cells (CD45⁺CD11b⁺) showed characteristic morphology of myeloid progenitor cells (Fig. 1f) and monocytoid and granulocytic cells (Fig. 1g), respectively. Sorted BMO-derived MSPCs (CD45⁺CD31⁺CD90⁺CD105⁺CD271⁺CD73⁺) were

adherent to plastic and possessed spindle-like morphology (Fig. 1h), characteristic of MSPCs¹⁹. Moreover, these cells expanded in culture and had serial replating capacity for up to 15 passages.

Next, we analyzed the spatial organization of the three main cell types by fluorescence microscopy. To increase the depth of imaging, we applied two-photon microscopy, allowing us to capture fluorescent signals of up to 845 μm depth. These studies confirmed the presence of vascular, hematopoietic and mesenchymal structures throughout the whole organoid (Fig. 1i and Supplementary Video 1). Confocal microscopy revealed spherical shaped CD45⁺ hematopoietic cells embedded into a network of CD31⁺ vascular structures and CD271⁺ stromal cells, which were visualized by three-dimensional (3D) surface rendering (Fig. 1j,k and Supplementary Fig. 3). Importantly, the spatial architecture of BMOs generated from different iPSC cell lines was comparable (Extended Data Fig. 2a–c). Moreover, we examined the spatial localization of CD45⁺ hematopoietic cells in the BMO by 3D surface rendering and subsequent statistical analysis, indicating their distribution throughout the organoid (Extended Data Fig. 2d,e and Supplementary Video 2). Thus, our protocol enables the generation of BMOs derived from various iPSC cell lines and donor backgrounds. BMOs self-organized into spatially defined 3D structures and consisted of key cell types characteristic of the human BM niche.

Mesenchymal and vascular spatial architecture

The BM niche sustains a dynamic interplay between perivascular stromal cells and vascular ECs, orchestrating a microenvironment crucial for hematopoiesis and maintaining HSC functions². Perivascular platelet-derived growth factor beta (PDGFR β)⁺ mural cells cover ECs, thereby supporting and promoting vasculogenesis²⁰. Confocal microscopy of BMOs revealed a vessel-like network of CD31⁺ ECs covered by PDGFR β ⁺ pericytes (Fig. 2a and Extended Data Fig. 3a,b). Interestingly, the formation of PDGFR β ⁺ pericytes changed during the differentiation process. Whereas on day 10 of differentiation, finger-like extensions of PDGFR β ⁺ pericytes were adjacent to ECs (Fig. 2b), upon organoid maturation on day 21 PDGFR β ⁺ pericytes were enveloping CD31⁺ cells (Fig. 2b,h and Supplementary Fig. 4a), resembling pericytes surrounding endosteal arterioles and Type-H vessels in mice²¹. Next, we examined the spatial distribution of CXCL12⁺ cells, crucial for retention and maintenance of HSCs and hematopoietic progenitors in the BM niche²². Remarkably, BMOs contained a perivascular network of CXCL12⁺ cells (Fig. 2c and Extended Data Fig. 3b) with extending protrusions towards the endothelium (Fig. 2d,h and Supplementary Fig. 4a), reminiscent of CXCL12-abundant reticular (CAR) cells^{6,22}. Nestin-expressing perivascular mesenchymal stem cells, known to support and regulate hematopoiesis²³, are located in endosteal regions in spatial association with HSCs and possess multilineage and self-renewal capacity in mice²³ and human fetal BM²⁴. We identified Nestin⁺ stromal cells in spatial relationship to CD31⁺ vessels and CD45⁺ hematopoietic cells in our BMOs by confocal and two-photon microscopy (Fig. 2e,f,h; Extended Data Fig. 3c and Supplementary Video 3). Confocal microscopy revealed Nestin⁺ processes of perivascular cells lining the vascular structures as seen in BM *in vivo* (Fig. 2e,h and Supplementary Fig. 4a)^{23,24}. Leptin receptor (LepR), an additional key marker for mesenchymal niche cells in the BM²⁵, was distributed rather broadly on stromal cells (Fig. 2g,h and Supplementary Fig. 4a). In addition, we confirmed surface expression of LepR in around 69% of mesenchymal cells (CD45⁺CD31⁺CD271⁺) (Extended Data Fig. 3d,e), validating the presence of LepR-expressing cells in the BMO.

Next, we aimed at characterizing the vessel structure^{21,25,26}. By applying clearing methods before imaging (Supplementary Fig. 4b) and subsequent 3D surface rendering, we confirmed the presence of vascular structures throughout the whole organoid (Fig. 2i, Supplementary Fig. 4c and Supplementary Video 4). ECs formed an envelope around the BMO (Extended Data Fig. 3f) and were also partially positive for




Fig. 1 | Generation of human iPSC-derived BMOs and analysis of cellular composition by flow cytometry and microscopy. a, Schematic illustration of the workflow for BMO generation. **b**, Representative bright-field images of iPSC1-derived embryoid bodies on day 0 and day 4, sprouting embryoid bodies on day 6 and differentiated BMOs on day 17 of $n = 5$ independent differentiations. **c**, Joint t -SNE visualization of day 17 flow cytometric data of $n = 3$ independent differentiations resulting in 105,000 cells. Expression of each lineage marker is shown in the t -SNE plots. Color correlates with intensity of expression (red, high expression; blue, low expression). **d**, Overlay of manually gated populations on t -SNE projection. Subsets defined as endothelial ($CD45^+ CD31^+$), hematopoietic ($CD45^+$), myeloid ($CD45^+ CD11b^+$) and mesenchymal ($CD45^+ CD31^+ CD271^+$) cells. HSPCs as $CD45^+ CD11b^+ CD34^+$ and MSPCs as $CD45^+ CD31^+ CD271^+ CD90^+ CD105^+ CD73^+$. Detailed gating strategy is outlined in Extended Data Fig. 1a. **e**, Quantification of frequencies of manually gated cell types for $n = 5$ independent differentiations.

Data are presented as mean values \pm s.e.m. **f,g**, Representative bright-field microscopy of sorted and May-Gruenwald-Giemsa-stained HSPCs (**f**) and $CD45^+ CD11b^+$ myeloid cells (**g**) of $n = 3$ independent differentiations. Characteristic high nuclear-to-cytoplasm ratio of HSPCs. $CD11b^+$ myelomonocytic cells, including monocytic cells (bean-shaped nucleus, a pale cytoplasm and fine granules) and immature neutrophil granulocyte characterized by the band-shaped nucleus. **h**, Morphology of sorted MSPCs in culture by phase-contrast. Representative image of $n = 6$ experiments with iPSC1 and iPSC2. **i**, Analysis of a representative whole-mount organoid (iPSC1, day 21) stained with indicated antibodies using two-photon microscopy of $n = 3$ independent differentiations. **j**, Surface rendering of a 3D z-reconstruction from a confocal image displaying $CD45^+$ cells in $CD31^+$ and $CD271^+$ niche cells. **k**, Still image from Supplementary Video 5. Angular view of **j** to visualize 3D architecture. Scale bars, **b**, 500 μ m (day 6 inset 100 μ m); **f-h**, 20 μ m; **i**, 100 μ m; **j,k**, 50 μ m.

CD34, as evidenced by immunohistochemical staining of BMO sections (Extended Data Fig. 3g). Quantitative assessment of vascular structures²⁷ confirmed complex network connectivity (mean branching index 186 junctions mm⁻²) (Extended Data Fig. 3h and Supplementary Fig. 4d,e). Importantly, CD31⁺ ECs were covered by a Collagen IV (Col IV)⁺ basement membrane (Fig. 2j). Transmission electron microscopy (TEM) revealed ECs to be connected by numerous tight junctions (Fig. 2k and Extended Data Fig. 3i). Moreover, ECs contained Weibel–Palade bodies and were enclosed by pericytes (Fig. 2l and Extended Data Fig. 3i). Orthogonal two-dimensional analysis documented the formation of a lumen in the vascular network (Extended Data Fig. 3l), which was confirmed by TEM of organoid sections (Fig. 2l). Remarkably, microscopic analysis of hematoxylin-eosin (H/E) stained organoid sections and TEM disclosed capillary-like structures containing round hematopoietic cells in the vessel lumen (Fig. 2m,n and Extended Data Fig. 3j,k). This observation was corroborated by 3D surface rendering of confocal microscopic images demonstrating CD31⁺ vessels enclosing CD45⁺ hematopoietic cells (Fig. 2o; Extended Data Fig. 3m,n and Supplementary Videos 5 and 6). These data support the notion that the vascular network in the BMO consists of bona fide blood vessels encompassing hematopoietic cells in their lumen. Together, these findings indicate that the endothelial and mesenchymal BMO compartments recapitulate key structural features and cell compositions of the human BM niche.

Functional properties of MSPCs and vascular network

To test the multipotency of BMO-derived immunophenotypic MSPCs, we performed trilineage differentiation assays (Extended Data Fig. 4a). Remarkably, when placed into the respective conditioned medium, isolated MSPCs from both iPSC1- and iPSC2-derived BMOs had the capacity to differentiate into osteogenic, adipogenic and chondrogenic cells, as visualized by Alizarin Red staining of calcium deposits, Oil-red-O staining of lipid vacuoles and Alcian-blue staining of glycosaminoglycans, respectively (Extended Data Fig. 4b and Supplementary Fig. 5a,b). These findings indicate the existence of MSPCs in the BMO.

To investigate functional properties of the vascular network in vivo, we transplanted mature BMOs under the renal capsule of immunodeficient NOD/SCID/IL2Rγ^{null} (NSG) mice^{16,28} (Extended Data Fig. 4c). Macroscopic analysis showed growth up to 7 months after transplantation (Extended Data Fig. 4d). Flow cytometry analysis at 3 months after transplantation indicated continued presence of the main BMO cell types, albeit at low numbers (Supplementary Fig. 5e,f). Histological analysis of organoid sections after transplantation displayed blood vessels filled with erythrocytes (Extended Data Fig. 4e). We confirmed their BMO origin by human-specific CD31 staining (Extended Data Fig. 4f and Supplementary Fig. 5c,d). Flow cytometry analysis at 3 and 7 months after transplantation detected human CD45⁺ (hCD45⁺) cells in the BM of a proportion of transplanted mice (Extended Data Fig. 4g,h and Supplementary Fig. 5g).

Moreover, hCD45⁺ were detected at low frequencies in the blood of transplant recipients (Extended Data Fig. 4i), indicating organoid access to the murine vasculature permissive for circulation of BMO-derived human CD45⁺ cells. To verify vascular interconnection, we intravenously injected fluorescently labeled dextran into NSG mice hosting the transplanted BMOs (Extended Data Fig. 4j). Using confocal microscopy, we detected dextran in the lumen of hCD31 positive vessels, confirming vascular connection (Extended Data Fig. 4j and Supplementary Fig. 5h,i).

Granulopoiesis

Next, we investigated maturation of neutrophil granulocytes by flow cytometry^{29–31} (Fig. 3a,b and Supplementary Fig. 6a,b). Based on expression of specific cell surface markers^{29–31}, neutrophil progenitor stages ProNeu1 (CD14⁺CD45⁺Siglec8⁺CD11b⁺CD49d^{high}SSC^{low}), ProNeu2 (CD14⁺CD45⁺Siglec8⁺CD11b⁺CD49d^{high}SSC^{high}) and PreNeu (CD14⁺CD45⁺Siglec8⁺CD11b⁺CD49d⁺CD101⁺), as well as immatureNeus (CD14⁺CD45⁺Siglec8⁺CD11b⁺CD49d^{low}CD101⁺CD35⁺CD16⁺) and matureNeus (CD45⁺Siglec8⁺CD11b⁺CD49d^{low}CD101⁺CD35⁺CD16⁺) were identified in BMOs derived from iPSC1 (Fig. 3a–c and Supplementary Fig. 7a,b) and iPSC2–5 (Supplementary Fig. 7). Light microscopic analysis of flow-sorted and Giemsa-stained cells showed that defined stages of BMO-derived neutrophil granulocytes morphologically resemble their counterparts in the human BM (Fig. 3d and Supplementary Fig. 6c). Immunofluorescent staining for the key neutrophil markers S100A8/A9 and myeloperoxidase (MPO) confirmed expression of both S100A8/A9 and MPO in cells in the BMOs, some of them exhibiting a banded or segmented nucleus indicative of myeloid maturation (Fig. 3e,f). Immunohistochemical studies validated expression of MPO by myeloid cells (Fig. 3g), and TEM analysis revealed the existence of cells with electron-dense cytoplasmic granules, a segmented nucleus and heterochromatin formation at the nuclear margin (Fig. 3h), which are characteristic features of neutrophil granulocytes. These findings indicate that the BMO niche promotes maturation of neutrophil granulocyte-like cells without the addition of lineage-directing cytokines, such as granulocyte colony stimulating factor (G-CSF). To examine the responsiveness of the granulopoietic compartment in the BMOs to inflammatory stimuli, as reported for emergency granulopoiesis in mice^{29,32}, we simulated inflammation by addition of lipopolysaccharide (LPS) derived from gram-negative *Escherichia coli* bacteria or heat-killed gram-positive *Listeria monocytogenes* to the BMOs (Fig. 3i). Subsequent analysis of the BMO supernatant revealed increased secretion of the inflammatory cytokines IL-6, IL-8 and G-CSF after 4 h, which increased after 24 h (Fig. 3j). Simultaneously, analysis of the neutrophil progenitor subpopulations showed an increase in the PreNeu subset compared with unstimulated controls after 24 h (Fig. 3k and Supplementary Fig. 6d). These results are consistent with findings in mice²⁹ and suggest that BMOs provide a model to study emergency granulopoiesis in a human context³².


Fig. 2 | Spatial architecture of BMOs recapitulates key features of mesenchymal and vascular human BM niche. **a**, Confocal images of immunostaining of CD31 (ECs) and PDGFRβ (pericytes) in a BMO to visualize vascular network and PDGFRβ⁺ pericytes. **b**, Analysis of pericyte–EC association on day 10 and day 21 of differentiation using confocal microscopy. Top, finger-like extensions of PDGFRβ⁺ pericytes on day 10 of differentiation. Bottom, tight association of a PDGFRβ⁺ pericyte with an EC on day 21 of differentiation. **c**, Analysis of CXCL12 expression in specific cell subsets throughout the organoid visualized by confocal microscopy. **d**, Analysis of CXCL12-expressing pericytes in close association to ECs by confocal microscopy. **e**, Nestin⁺ cells lining CD31⁺ vessels and CD45⁺ hematopoietic cells. Note CD45^{high}-expressing cell with banded nucleus. **f**, Analysis of Nestin expression in spatial association with CD31⁺ vessels and CD45⁺ hematopoietic cells by two-photon microscopy; z-dimension, 515 μm. **g**, Analysis of LepR expression by confocal microscopy. In **a–g**, *n* = 3 independent experiments. **h**, 3D surface rendering of mesenchymal niche cells


and vessels. **i**, 3D surface rendering of optically cleared whole organoid stained for CD31; still frame from Supplementary Video 4. **j**, ECs are covered by a Col IV⁺ basement membrane. In **i** and **j**, *n* = 3 independent experiments. **k**, Analysis of a pericyte and EC connected by tight junctions (TJ) by TEM. **l**, TEM analysis of an organoid section showing capillary-like structure by an EC (E) forming a lumen (L) and enclosed by a pericyte (P); asterisk, Weibel–Palade bodies. **k** and **l** are representative micrographs of sections from *n* = 2 independent experiments. **m**, Histological sections reveal morphologically hematopoietic cells in lumen of vessel-like structures by H/E stain; *n* = 3 independent experiments. **n**, TEM analysis of an organoid section showing ECs (E) encompassing round cells resembling myeloid cells (M). Representative micrographs of sections from *n* = 2 independent experiments. **o**, Hematopoietic cells inside vessel lumen visualized by 3D rendering; still frame from Supplementary Video 5. Scale bars, **a, f**, 100 μm; inset in **i** 50 μm; **b–e**, 50 μm; **g, m**, 20 μm; **h, j**, 10 μm; **k, l**, 1 μm; **n, o**, 5 μm.


Cell type analysis by single-cell transcriptomics


To characterize the cellular composition of the organoid model on a molecular level, we performed single-cell RNA sequencing (scRNA-seq)


of dissociated BMOs from two independent batches of differentiation (Supplementary Fig. 8a,b). After quality control, our dataset comprised a total number of 31,040 cells (Fig. 4a,c). Unsupervised clustering

Mesenchymal niche cells 



Vascular network 





revealed three main distinct populations, which were identified as hematopoietic, endothelial and mesenchymal lineages, respectively (Fig. 4a,b). When compared with an atlas of human gastrulation³³, a minor cluster of cells was enriched for primitive streak genes (Fig. 4c,d), suggesting the presence of a small subset of immature progenitor cells in the organoid. Additionally, we noted the presence of a small epithelial cell cluster (Fig. 4c,d). We observed a high degree of consistency

in the overall cell type composition in comparison with the clustering of immunophenotypic data (Fig. 1d and Fig. 4a), with minor shifts in the frequency distribution of the individual cell types (Supplementary Fig. 8c and Fig. 1e).

Using previously published molecular signatures of human fetal BM³⁴ and other published datasets³⁵⁻³⁷, we identified principal hematopoietic cell types in the hematopoietic cluster, marked

Fig. 3 | BMOs model granulopoiesis. **a**, Gating scheme for neutrophil differentiation analysis of dissociated BMOs on day 21 of differentiation by flow cytometry. **b**, Histogram of surface marker expression of distinct neutrophil progenitor stages until mature neutrophil-like state of BMO-derived neutrophils. **c**, Quantification of the frequency of neutrophil progenitor subpopulations in the CD45⁺ population; $n = 6$ independent experiments. **d**, May–Gruenwald–Giemsa staining of BMO-derived sorted neutrophil progenitors and mature neutrophil-like cells. Representative images from $n = 2$ independent experiments. **e, f**, Confocal imaging of immunostaining of S100A8/A9 (**e**) and MPO (**f**) in cells with banded/segmented nucleus. Insets, magnified images of the rectangle areas. DAPI, 4,6-diamidino-2-phenylindole. **g**, Analysis of MPO expression of a BMO section by immunohistochemistry. Inset,

magnified image of the rectangle area. Images in **e–g** are representative images from $n = 3$ independent experiments. **h**, TEM image of typical morphology of a cell resembling a neutrophil granulocyte in the organoid. Representative micrograph of sections from $n = 2$ independent experiments. **i**, Experimental layout used to model inflammation. ELISA, enzyme-linked immunosorbent assay. **j**, Cytokine levels in supernatant of stimulated and unstimulated BMOs, LPS $n = 5$ independent experiments and *Listeria* (*L. monocytogenes*), $n = 3$ independent experiments. Unstim., unstimulated. **k**, Quantification of the fold change of the PreNeu population upon stimulation in BMOs; LPS, $n = 5$ independent experiments and *Listeria* $n = 3$ independent experiments. Scale bars, **d**, 20 μm ; **e, f**, 10 μm ; **g**, 50 μm (inset 10 μm); **h**, 2 μm . Data in **c, j** and **k** are presented as mean values \pm s.e.m.

by expression of *PTPRC* (CD45), *SPN* (CD43) and *RUNX1*. This cluster comprised not only myeloid progenitors, as well as neutrophils, monocytes and macrophages, but also eosinophil/basophil, mast cells, dendritic cells (DC), megakaryocytic and, importantly, lymphoid progenitor cells (Fig. 4b,d). These latter express markers of lymphoid-primed multipotent progenitors, for example, *IL7R* and *BCL11A*³⁴, as well as marker genes that are indicative of early lymphoid progenitors such as *LTB* and *FLT3* (ref. 34) (Fig. 4d and Extended Data Fig. 5a,b). We validated the expression of IL-7 receptor (IL7R) and CD10 corresponding to markers for lymphoid progenitors^{38,39} on a subset of CD34⁺CD90^{mid}CD45⁺ cells by flow cytometry (Extended Data Fig. 5c,d). Moreover, we confirmed the presence of CD41⁺CD61⁺CD42⁺ megakaryocyte-like cells by a series of various methods revealing immunophenotypic and morphological characteristics of megakaryocytes (Extended Data Fig. 5e–h).

Cells in the endothelial cluster, defined by expression of *PECAM1* (CD31), *CDH5* (VE-Cadherin) and *KDR* (VEGFR-2), also expressed canonical genes of arterial ECs, such as *EFNB2*, *GJA4* and *CXCR4* (ref. 37). Notably, these ECs also highly expressed Notch signaling pathway genes (*DLL4*, *NOTCH1*, *NOTCH4*, *HEY1*), which had previously been reported to be important for definitive hematopoiesis in vivo³⁷ and differentiation of definitive HE from PSCs in vitro⁴⁰. Accordingly, a subpopulation was characterized by marker genes of arterial pre-HE³⁷ (Fig. 4e,f). We confirmed expression of arterial surface markers (*DLL4*, *CXCR4*) on CD31⁺ ECs by flow cytometry (Extended Data Fig. 5m,n).

In the mesenchymal cluster, defined by *COL1A1* (Collagen I), *PDGFRA* and *PDGFRB*, we could distinguish pericytes (*PDGFRB*, *ANGPT1*, *MCAM*, *RGSS5*)²⁰ and vascular smooth muscle cells (*ACTA2*, *TAGLN*)^{6,36} (Fig. 4g,h). Moreover, in line with our immunofluorescence results, cells in the mesenchymal cluster expressed known HSC-supporting genes, such as *CXCL12* (ref. 22), *NES* (Nestin)²³, *CSPG4* (NG2)²⁶ and *LEPR*²⁵ (Extended Data Fig. 5i). Furthermore, we identified chondrogenic precursor cells expressing *HAPLN1* (ref. 34), *SOX5* (ref. 41) and *DCN*⁴², as well as osteogenic precursors marked by the transcription factors *PRRX1* (ref. 43), *MSX1* (ref. 44) and *CPE*³⁴ (Fig. 4g,h). Histological staining of organoid sections from day 45 of differentiation revealed the presence of rare Alcian-blue positive cells with an oval shaped nucleus, indicative of mucopolysaccharides (Extended Data Fig. 5j). Additionally, we detected expression of Collagen II, which is associated with chondrocytes, by immunofluorescence microscopy. (Extended Data Fig. 5k). The nuclear expression of *PRRX1* in mesenchymal cells was validated through immunofluorescence microscopy (Extended Data Fig. 5l).

Fig. 4 | Single-cell transcriptomic analysis of BMOs identifies diverse cell populations. **a**, Coarse-grained clustering of scRNA-seq data reveals three main populations comprising endothelial, hematopoietic and mesenchymal cells. **b**, Expression of characteristic markers indicative of the three main populations. **c**, Uniform manifold approximation and projection (UMAP) projection of a total number of 31,040 cells colored according to detailed cell type annotations. eo/baso, eosinophil/basophil; GMP, granulocyte/monocyte-progenitor; MPP, multipotent progenitor; LMPP, lymphoid-primed multipotent progenitors;

Overall, the single-cell transcriptomic data supports the notion that BMOs contain highly diverse cell populations reminiscent of fetal BM at the molecular level.

Characterization of HSPCs in BMOs


In our scRNA-seq dataset we also identified a distinct population of cells expressing signature genes of human fetal HSCs/MPPs^{34,37,45,46} (Fig. 4c,d). During human embryonic development, definitive long-term HSCs first emerge in the aorta-gonad-mesonephros (AGM) region, migrate to the liver and ultimately colonize the fetal BM at around 11–12 weeks post conception^{3,34,47}. We compared gene expression signatures in BMOs with previously reported molecular signatures of human fetal HSCs in yolk sac, AGM, fetal liver and fetal BM^{34,37,45,46}. Our findings revealed that BMO-derived HSPCs expressed key transcription factors associated with definitive HSCs, which are essential for HSC self-renewal (*MLL3*), HSC maintenance (*MECOM*) and undifferentiated HSPCs (*HLF*) (Fig. 5a). *HLF* emerged as the most distinctive marker for this cluster in our dataset, in line with human fetal HSCs in the AGM³⁷. Additionally, canonical HSC marker genes (*RUNX1*, *SPINK2*, *HOPX*, *RAB27B*, *MYB*), as well as surface markers indicative of definitive HSCs (*KIT*, *CD74*, *ITGA4*) exhibited high expression levels (Fig. 5a). While levels of medial HOX genes (*HOXA9*, *HOXA10*) were low, posterior HOX genes (*HOXB9*, *HOXB7*) were prominently expressed. BMO-derived HSPCs expressed not only embryonic genes (*LIN28B*, *IGFBP2*), but also maturity markers, which are present only from the fetal liver stage onwards and associated with maturation of HSCs³⁷ (Fig. 5b). The latter include the transcription factor *MSI2* and surface marker *SELL* (CD62L) (Fig. 5b), as well as expression of major histocompatibility complex class II molecules (Fig. 5c). Together our data support the notion that the multilineage hematopoietic compartment in BMOs, including lymphoid progenitor cells, and the presence of arterial-type ECs recapitulates definitive hematopoiesis^{47,48}.


To examine the multilineage differentiation capacity of BMO-derived HSPCs, we performed colony-forming unit (CFU) assays (Supplementary Fig. 9a). FACS-sorted HSPCs gave rise mainly to granulocyte-macrophage progenitor cells (CFU-GM), but also multipotent granulocyte, erythroid, macrophage and megakaryocyte progenitor cells (CFU-GEMM) and erythroid progenitors (BFU-E) (Supplementary Fig. 9a,b). Isolated HSPCs from iPSC2-derived BMOs also gave rise to CFU-GEMM and CFU-GM, yet not to typical BFU-E colonies (Supplementary Fig. 9c,d). Second, to examine the lymphoid differentiation potential of BMO-derived HSPCs⁴⁸, we adapted an artificial thymic organoid (ATO) differentiation system, which has

MEP, megakaryocyte/erythroid progenitor; MK, megakaryocyte; mono. mac., monocytoic macrophage; PS, primitive streak-like. **d**, Expression of marker genes for annotation of hematopoietic lineages. Neutr. prog., neutrophil progenitor; mono. prog., monocyte progenitor. **e**, Expression of marker genes for endothelial subtypes. **f**, UMAP projection for arterial endothelial and pre-HE cells coexpressing displayed marker genes. **g**, Expression of marker genes for mesenchymal cell clusters. **h**, UMAP projection of distinct mesenchymal subsets coexpressing marker genes.

been established previously for primary human HSPCs⁴⁹ and PSCs⁵⁰ (Fig. 5d and Supplementary Fig. 9e). Following 3 weeks of ATO culture, we observed the emergence of CD5⁺CD7⁺ lymphoid cells.

Notably, most of these cells (around 74%) were CD4⁺CD8⁺ double-positive and around 27% expressed CD3 and TCRαβ, phenotypically resembling T cells (Fig. 5e,f and Supplementary Fig. 9f). Finally, to





determine engraftment potential of BMO-derived HSPCs *in vivo*, we transplanted sorted BMO-derived CD34⁺ cells or human cord blood (CB) CD34⁺ cells as controls via intravenous injection into immunodeficient major histocompatibility complex-II-deficient NSG-HLA-DQ8 transgenic mice (NSG-HLA-DQ8)⁵¹ (Fig. 5g). Serial blood draws were

performed at 5, 8 and 10 weeks post transplantation, followed by an analysis of human chimerism by flow cytometry. Eight weeks after transplantation, human CD45⁺ cells were detectable in the peripheral blood in 44% of the transplanted animals, indicating partial engraftment (Fig. 5h). Flow cytometry analyses of the BM revealed the presence

Fig. 5 | Molecular signature resembling fetal HSCs, lymphoid potential and engraftment potential of BMO-derived HSPCs. **a–c**, scRNA-seq of BMOs, revealing expression of canonical, early and definitive/surface HSC marker genes (**a**), marker genes for immature and mature states of HSCs (**b**) and HLA-class II molecule genes indicative of maturation (**c**). Hem., hematopoietic. **d**, Experimental layout for generation of ATOs with BMO-derived CD34⁺ cells and their analysis by flow cytometry. **e**, Flow cytometric analysis of surface marker expression of live, CD14⁺, mCD29⁺, CD56⁺ and CD45⁺ cells. **f**, Quantification of frequencies of lymphoid populations shown in **e**, $n = 3$ independent batches of BMO and ATO differentiation. **g**, Experimental layout for testing of in vivo engraftment potential. **h**, Quantification of frequencies of human chimerism in

peripheral blood of transplanted mice at weeks 5, 8, 10 and 12. **i**, Flow cytometric analysis of human chimerism (hCD45⁺ cells) in BM of mice transplanted with BMO-derived HSPCs, CB controls or nontransplanted controls. **j**, Quantification of frequencies of hCD45⁺ cells in BM of mice transplanted with BMO-derived HSPCs after 10 and 12 weeks; $n = 2$ independent transplantations with two independent batches of BMO differentiation. **k**, Flow cytometric analysis of surface marker expression of hCD45⁺ engrafted cells in BMO-derived HSPC transplant and CB controls. **l**, Quantification of frequencies of hCD20⁺ (B cells), hCD33⁺ (myeloid cells) and hCD3⁺ (T cells) of engrafted hCD45⁺ cells in BM of $n = 2$ BMO-derived HSPC-transplanted and $n = 4$ CB-transplanted animals. Data in **f** and **l** are presented as mean values \pm s.e.m.

of hCD45⁺ cells in one out of five mice after 10 weeks (0.94% hCD45⁺) and one out of four mice after 12 weeks (2.27% hCD45⁺) (Fig. 5i,j and Supplementary Fig. 9g,h). Human CD45⁺ cells in recipient mice contained CD20⁺ cells (B cell marker), as well as CD33⁺ cells (myeloid cell marker). Similar frequencies were obtained in mice that were transplanted with CB CD34⁺ cells. We also detected a few hCD45⁺ cells expressing CD3, indicative of T cells (Fig. 5k,l and Supplementary Fig. 9i). These data provide evidence for engraftment and multilineage differentiation potential of the HSPCs generated in our BMO model.

Modeling hematopoietic development and genetic disease

Having identified arterial pre-HE³⁷ resembling cells by scRNA-seq (Fig. 4e,f and Fig. 6a), we next set out to study endothelial-to-hematopoietic transition (EHT). During human embryonic development, definitive HSCs emerge from specialized ECs lining the ventral wall of the dorsal aorta^{37,47,52}. This involves the transition of arterial ECs to pre-HE and HE towards HSCs, characterized by the sequential downregulation of arterial endothelial genes and the upregulation of HSC-specific genes³⁷. We identified a subset of cells in the endothelial cluster expressing markers associated with pre-HE³⁷, including *IL33*, *SULF1*, *GJA5* and *HEY2*, although *ALDH1A1* expression was limited (Fig. 6b). Whereas we could not distinguish a specific HE subcluster, cells in the pre-HE cluster exhibited key HE genes such as *KCNK17* (ref. 37) and displayed low levels of *RUNX1*, indicating initiation of hemogenic transition (Fig. 6b). Moreover, while Wnt inhibitor genes (*DKK1*, *DKK2*) were low, TGF β /BMP-inhibitor genes (*SMAD6*, *SMAD7*) previously reported to be essential for EHT³⁷, were upregulated in the pre-HE cluster (Fig. 6c). Thus, we identified molecular signatures of EHT processes in our BMO. To capture intermediate cellular differentiation states in our flow cytometry data, we analyzed protein expression by unsupervised clustering using the FlowSOM algorithm⁵³ (Fig. 6d,e). The endothelial compartment contained additional subpopulations. Cluster 3 cells coexpressed CD31, CD34, CD90 (Thy1)⁵⁴ and CD105 (Endoglin)⁵⁵ and were negative for CD45, resembling human HE and HSCs. The adjacent cluster 4, defined by CD31^{low}CD34⁺ and CD45⁺ cells, constituted the manually gated HSPC cluster (Fig. 6d,e). Decreasing CD31 expression while upregulating CD34 and CD45 reflects the immunophenotypic sequence of cells that undergo EHT⁵⁶.

Morphologically, EHT is characterized by changes of arterial ECs⁵² (Fig. 6f) and expression of the transcription factor RUNX1 (ref. 57). Confocal imaging showed distinct clusters of RUNX1-expressing cells with some of these cells coexpressing CD31 and remaining attached to the endothelial wall (Fig. 6g). Furthermore, H/E staining of organoid sections revealed rounding up of cells from the endothelial lining (Fig. 6h). This finding was also observed in histological sections of BMOs stained for CD34 (Fig. 6i). Immunofluorescence of immature organoids (day 10) followed by 3D surface rendering demonstrated CD31⁺ cells budding off from endothelial structures (Fig. 6j) and revealed CD34 expression of vessels, as well as round CD34⁺ cells attached to the endothelial lining inside the vessel lumen (Fig. 6k, Supplementary Fig. 10a and Supplementary Video 7), thus reflecting findings of EHT in vivo⁵². These data suggest that BMOs give rise to arterial-type ECs, pre-HE and HE, which transition into human HSPC-like cells by EHT, thus modeling features of developmental processes in human hematopoiesis.

Finally, we tested whether our BMOs can be used as a model system to recapitulate the phenotype of monogenic BM diseases. Children with vacuolar protein sorting 45 homolog (*VPS45*) deficiency clinically present with neutropenia and myelofibrosis in the first year of life and progress to overt BM failure^{58,59}. Their BM is hypercellular and shows myeloid hyperplasia associated with increased apoptosis and functional deficiencies of neutrophils^{58,59}. We generated BMOs from an iPSC line, in which the homozygous Thr224Asn mutation in *VPS45* had been introduced by CRISPR–Cas9-mediated gene editing¹² (Fig. 6l and Supplementary Fig. 10b,c). The composition of hematopoietic as well as niche cells was comparable between isogenic control BMOs and *VPS45*-mutant BMOs (Supplementary Fig. 10d). In contrast to controls, *VPS45*-mutant BMOs showed increased deposition of reticulin fibers (Fig. 6m), reminiscent of myelofibrosis in BM biopsies of *VPS45*-deficient patients^{58,59}. This was accompanied by expansion of alpha smooth muscle actin (α SMA) expressing myofibroblast-like stromal cells (Fig. 6n,o), previously described as critical drivers of myelofibrosis²⁰. Flow cytometric analysis of *VPS45*-mutant BMOs showed higher numbers of matureNeus in comparison with controls (Supplementary Fig. 10e) resembling myeloid hyperplasia and a significant increase in AnnexinV expression on *VPS45*-mutant matureNeus

Fig. 6 | Modeling features of hematopoietic development and genetic disease in BMOs.


a, UMAP projection of pre-HE subpopulation in the endothelial cluster. **b**, Dotplot shows expression of key marker genes for arterial ECs, pre-HE, HE and HSPCs during EHT. **c**, Dotplot for expression of TGF β /BMP or Wnt inhibitor genes in different subsets. **d**, Unsupervised clustering of flow cytometry populations using the FlowSOM algorithm reveals heterogeneity in the endothelial cluster. **e**, Heatmap of mean fluorescence intensity (MFI) of indicated surface marker expression in BMO cell clusters 1–5 identified by FlowSOM algorithm. **f**, Scheme depicting morphological changes during transition from HE to HSPCs. **g**, Coexpression of RUNX1 and CD31 in clusters of cells by confocal imaging. RUNX1⁺ cells indicated by round morphology (arrow) are attached to endothelial layer. **h**, i, HE- (**h**) and CD34- (**i**) stained organoid section indicating budding of hematopoietic cells from the endothelial wall. **j**, Surface rendering of immunostaining of CD31 in the BMO at day 10. **k**, Surface

rendering of immunostaining of CD31, CD34 and CD45 inside a vessel lumen in the BMO at day 10; still frame from Supplementary Video 7. Images in **g–k** are representative images from $n = 3$ independent experiments. **l**, Modeling of *VPS45* deficiency in BMOs and follow-up analysis. Schematic overview of gene editing and experimental set-up to create an isogenic *VPS45* mutant iPSC cell line. **m**, Histological comparison of control and *VPS45* mutant BMOs by H/E and Gomori stain reveals reticulin fibrosis in *VPS45* mutant BMOs; $n = 8$ organoids for each condition of two batches. **n**, Alpha SMA expression in control and *VPS45*[−] mutant BMOs analyzed by immunofluorescence. **o**, Quantification of MFI of SMA expression; four different regions of $n = 5$ organoids per condition of two batches. **** $P < 0.0001$, unpaired two-tailed t -test. **p**, Quantification of Annexin MFI on matureNeus by flow cytometry; $n = 3$ independent experiments. * $P = 0.0155$, unpaired two-tailed t -test. Data in **o** and **p** are presented as mean values \pm s.e.m. Scale bars, **g**, **j**, 20 μ m; **h**, **i**, **m**, **n**, 50 μ m; **k**, 8 μ m.

(Fig. 6p and Supplementary Fig. 10f), indicating enhanced apoptosis of this subpopulation—a feature also observed in patients⁵⁹. Thus, BMOs may provide appropriate model systems for dissecting genes and pathways in previously intractable pathomechanisms of BM failure diseases.

Discussion

We here report the development of complex iPSC-derived human BMOs. Previously, approaches of generating a BMO⁶⁰ or BM-on-a-chip⁶¹ from primary human cells relied on tedious protocols for isolation of BM cells, which are often not easily obtainable. The BMO protocol offers



advantages in simplicity and reproducibility by using off-the-shelf products and commercial iPSC cell lines, being serum- and feeder-free and without requirement for hypoxic cultivation conditions. The successful generation of BMOs from renal epithelial cells may bear clinical significance, especially for pediatric patients, where urine samples can serve as a noninvasive, pain-free and efficient source for iPSCs^{62,63}.

Nevertheless, BMOs share common limitations associated with iPSC-derived tissues *in vitro*⁶⁴. Due to cellular immaturity, the BMOs are more similar to fetal rather than adult BM. Furthermore, they lack osseous trabeculae and neuronal cells.

Recently, human PSC-derived hematopoietic organoids^{9,65} generated hematopoietic cells with lymphoid potential, a vascular network and a subset of stromal cells; however, their stromal architecture was not described in detail. Here, advanced imaging techniques revealed a complex architecture of perivascular and endothelial niche cells in the BMOs and functional studies confirmed multipotency of MSPCs and connection of vessel structures *in vivo*. Additionally, BMOs contained immunophenotypically defined neutrophil progenitor subsets, supported the maturation of granulopoietic cells without addition of cytokines such as G-CSF and exhibited responsiveness to inflammatory stimuli.

Our data suggest that BMOs recapitulate aspects of definitive hematopoiesis, supported by molecular signatures of arterial ECs and pre-HE and lymphoid differentiation capacity of BMO-derived HSPCs. In parallel to our studies, Khan et al. developed human iPSC-derived BMOs, supporting leukemic cell engraftment and disease modeling¹⁰. Unlike our approach, their strategy yielded predominantly erythroid-myeloid cell types in the hematopoietic compartment, resembling extraembryonic-type hematopoiesis^{47,66}. As precise mesodermal patterning for induction of intraembryonic-type definitive hematopoiesis requires activation of Wnt-signaling and inhibition of activin/nodal-signaling^{9,48,65,66}, inclusion of a Wnt-activator (CHIR99021) and activin/nodal-inhibitor (SB431542) in our protocol might be key for differentiation of arterial-type ECs and emergence of HSPCs giving rise to a multilineage hematopoietic compartment in the organoid.

scRNA-seq identified a cell population in BMOs expressing genes of human fetal HSCs, including key HSC-associated factors like *RUNX1*, *SPINK2*, *MLLT3*, *MECOM* and *HLF*. The lack of *HOXA* patterning gene expression in our HSPC cluster, essential for true HSC generation⁶⁷, may result from lack of retinoid acid signaling, reflected by low *ALDH1A1* levels in the pre-HE cluster. However, they displayed canonical HSC genes and, to some extent, expression of fetal liver-associated genes, resembling in part both AGM and fetal liver HSCs³⁷. Remarkably, BMO-derived CD34⁺ cells showed engraftment potential upon transplantation into immunodeficient mice, albeit only in a subset of recipients. This is a noteworthy outcome, considering that successful transient engraftment of *ex vivo* differentiated iPSC-derived HSPCs without transgenic expression of transcription factors has been challenging. Luff et al.⁶⁸ recently reported engraftment of iPSC-derived hemogenic endothelium in murine BM up to 10 weeks. The presence of human chimerism at 10 and 12 weeks posttransplantation in our experiments underscores the encouraging engraftment potential of BMO-derived HSPCs. Addition of retinoic acid to the culture conditions as previously reported^{67,68} might induce a molecularly more mature HSPC population, which could enhance engraftment potential in the future.

Notably, gene-edited iPSC-derived BMOs modeled aspects of an inherited BM failure syndrome by recapitulating features of myelofibrosis alongside a hematopoietic phenotype. Existing models often rely on the addition of fibrosis-inducing agents¹⁰ or humanized PDX models⁶⁹. Thus, BMOs provide a platform to study genetic diseases in the context of a complex human niche.

Finally, since the lack of immune cells, vasculature and pericytes presents a common limitation of organoid models⁷⁰, another possible application of our method might be the combination of BMOs with other iPSC-derived organoids to form assembloids⁷⁰.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41592-024-02172-2>.

References

1. Doulatov, S., Notta, F., Laurenti, E. & Dick, J. E. Hematopoiesis: a human perspective. *Cell Stem Cell* **10**, 120–136 (2012).
2. Pinho, S. & Frenette, P. S. Haematopoietic stem cell activity and interactions with the niche. *Nat. Rev. Mol. Cell Biol.* **20**, 303–320 (2019).
3. Charbord, P., Tavani, M., Humeau, L. & Peault, B. Early ontogeny of the human marrow from long bones: an immunohistochemical study of hematopoiesis and its microenvironment. *Blood* **87**, 4109–4119 (1996).
4. Raaijmakers, M. H. G. P. et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. *Nature* **464**, 852–857 (2010).
5. Dong, L. et al. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. *Nature* **539**, 304–308 (2016).
6. Baccin, C. et al. Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization. *Nat. Cell Biol.* **22**, 38–48 (2020).
7. Baryawno, N. et al. A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. *Cell* **177**, 1915–1932.e16 (2019).
8. Mestas, J. & Hughes, C. C. W. Of mice and not men: differences between mouse and human immunology. *J. Immunol.* **172**, 2731–2738 (2004).
9. Motazedian, A. et al. Multipotent RAG1⁺ progenitors emerge directly from haemogenic endothelium in human pluripotent stem cell-derived haematopoietic organoids. *Nat. Cell Biol.* **22**, 60–73 (2020).
10. Khan, A. O. et al. Human bone marrow organoids for disease modelling, discovery and validation of therapeutic targets in hematological malignancies. *Cancer Discov.* **13**, 364–385 (2023).
11. Niwa, A. et al. A novel serum-free monolayer culture for orderly hematopoietic differentiation of human pluripotent cells via mesodermal progenitors. *PLoS ONE* **6**, e22261 (2011).
12. Frey, L. et al. Mammalian VPS45 orchestrates trafficking through the endosomal system. *Blood* **137**, 1932–1944 (2021).
13. Fan, Y. et al. HAX1-dependent control of mitochondrial proteostasis governs neutrophil granulocyte differentiation. *J. Clin. Invest.* **132**, e153153 (2022).
14. Fan, Y. et al. Analyzing mitochondrial respiration of human induced pluripotent stem cell-derived myeloid progenitors using Seahorse technology. *STAR Protoc.* **4**, 102073 (2023).
15. Linder, M. I. et al. Human genetic defects in SRP19 and SRPRA cause severe congenital neutropenia with distinctive proteome changes. *Blood* **141**, 645–658 (2023).
16. Wimmer, R. A. et al. Human blood vessel organoids as a model of diabetic vasculopathy. *Nature* **565**, 505–510 (2019).
17. Wimmer, R. A., Leopoldi, A., Aichinger, M., Kerjaschki, D. & Penninger, J. M. Generation of blood vessel organoids from human pluripotent stem cells. *Nat. Protoc.* **14**, 3082–3100 (2019).
18. Maaten van der, L. & Hinton, G. Visualizing data using t-SNE. *J. Mach. Learn. Res.* **9**, 2579–2605 (2008).
19. Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* **8**, 315–317 (2006).
20. Armulik, A., Genové, G. & Betsholtz, C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. *Dev. Cell* **21**, 193–215 (2011).

21. Kusumbe, A. P. et al. Age-dependent modulation of vascular niches for haematopoietic stem cells. *Nature* **532**, 380–384 (2016).
22. Greenbaum, A. et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. *Nature* **495**, 227–230 (2013).
23. Méndez-Ferrer, S. et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature* **466**, 829–834 (2010).
24. Pinho, S. et al. PDGFR α and CD51 mark human Nestin⁺ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. *J. Exp. Med.* **210**, 1351–1367 (2013).
25. Ding, L., Saunders, T. L., Enikolopov, G. & Morrison, S. J. Endothelial and perivascular cells maintain haematopoietic stem cells. *Nature* **481**, 457–462 (2012).
26. Kunisaki, Y. et al. Arteriolar niches maintain haematopoietic stem cell quiescence. *Nature* **502**, 637–643 (2013).
27. Zudaire, E., Gambardella, L., Kurcz, C. & Vermeren, S. A computational tool for quantitative analysis of vascular networks. *PLoS ONE* **6**, e27385 (2011).
28. Ishikawa, F. et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chain(null) mice. *Blood* **106**, 1565–1573 (2005).
29. Evrard, M. et al. Developmental analysis of bone marrow neutrophils reveals populations specialized in expansion, trafficking, and effector functions. *Immunity* **48**, 364–379.e8 (2018).
30. Kwok, I. et al. Combinatorial single-cell analyses of granulocyte-monocyte progenitor heterogeneity reveals an early uni-potent neutrophil progenitor. *Immunity* **53**, 303–318.e5 (2020).
31. Dinh, H. Q. et al. Coexpression of CD71 and CD117 identifies an early unipotent neutrophil progenitor population in human bone marrow. *Immunity* **53**, 319–334.e6 (2020).
32. Manz, M. G. & Boettcher, S. Emergency granulopoiesis. *Nat. Rev. Immunol.* **14**, 302–14 (2014).
33. Tyser, R. C. V. et al. Single-cell transcriptomic characterization of a gastrulating human embryo. *Nature* **600**, 285–289 (2021).
34. Jardine, L. et al. Blood and immune development in human fetal bone marrow and Down syndrome. *Nature* **598**, 327–331 (2021).
35. Velten, L. et al. Human haematopoietic stem cell lineage commitment is a continuous process. *Nat. Cell Biol.* **19**, 271–281 (2017).
36. Park, J.-E. et al. A cell atlas of human thymic development defines T cell repertoire formation. *Science* **367**, eaay3224 (2020).
37. Calvanese, V. et al. Mapping human haematopoietic stem cells from haemogenic endothelium to birth. *Nature* **604**, 534–540 (2022).
38. Kondo, M., Weissman, I. L. & Akashi, K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. *Cell* **91**, 661–672 (1997).
39. Galy, A., Travis, M., Cen, D. & Chen, B. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. *Immunity* **3**, 459–473 (1995).
40. Uenishi, G. I. et al. NOTCH signaling specifies arterial-type definitive hemogenic endothelium from human pluripotent stem cells. *Nat. Commun.* **9**, 1828 (2018).
41. Smits, P. et al. The transcription factors L-Sox5 and Sox6 are essential for cartilage formation. *Dev. Cell* **1**, 277–290 (2001).
42. Danielson, K. G. et al. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. *J. Cell Biol.* **136**, 729–743 (1997).
43. Liu, H. et al. Prrx1 marks stem cells for bone, white adipose tissue and dermis in adult mice. *Nat. Genet.* **54**, 1946–1958 (2022).
44. Zhang, X. et al. Msx1⁺ stem cells recruited by bioactive tissue engineering graft for bone regeneration. *Nat. Commun.* **13**, 5211 (2022).
45. Goh, I. et al. Yolk sac cell atlas reveals multiorgan functions during human early development. *Science* **381**, eadd7564 (2023).
46. Popescu, D.-M. et al. Decoding human fetal liver haematopoiesis. *Nature* **574**, 365–371 (2019).
47. Ivanovs, A. et al. Human haematopoietic stem cell development: from the embryo to the dish. *Development* **144**, 2323–2337 (2017).
48. Kennedy, M. et al. T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures. *Cell Rep.* **2**, 1722–1735 (2012).
49. Seet, C. S. et al. Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids. *Nat. Methods* **14**, 521–530 (2017).
50. Montel-Hagen, A. et al. Organoid-induced differentiation of conventional T cells from human pluripotent stem cells. *Cell Stem Cell* **24**, 376–389.e8 (2019).
51. Serr, I. et al. Type 1 diabetes vaccine candidates promote human Foxp3⁺Treg induction in humanized mice. *Nat. Commun.* **7**, 10991 (2016).
52. Boisset, J.-C. et al. In vivo imaging of haematopoietic cells emerging from the mouse aortic endothelium. *Nature* **464**, 116–120 (2010).
53. Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. *Cytom. A* **87**, 636–645 (2015).
54. Murray, L. et al. Enrichment of human hematopoietic stem cell activity in the CD34⁺Thy-1⁺Lin[−] subpopulation from mobilized peripheral blood. *Blood* **85**, 368–378 (1995).
55. Chen, C.-Z. et al. Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. *Proc. Natl Acad. Sci. USA* **99**, 15468–15473 (2002).
56. Oberlin, E., Tavian, M., Blazsek, I. & Péault, B. Blood-forming potential of vascular endothelium in the human embryo. *Development* **129**, 4147–4157 (2002).
57. North, T. et al. Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. *Development* **126**, 2563–2575 (1999).
58. Vilboux, T. et al. A congenital neutrophil defect syndrome associated with mutations in VPS45. *N. Engl. J. Med.* **369**, 54–65 (2013).
59. Stepsensky, P. et al. The Thr224Asn mutation in the VPS45 gene is associated with the congenital neutropenia and primary myelofibrosis of infancy. *Blood* **121**, 5078–5087 (2013).
60. Giger, S. et al. Microarrayed human bone marrow organoids for modeling blood stem cell dynamics. *APL Bioeng.* **6**, 036101 (2022).
61. Chou, D. B. et al. On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology. *Nat. Biomed. Eng.* **4**, 394–406 (2020).
62. Zhou, T. et al. Generation of human induced pluripotent stem cells from urine samples. *Nat. Protoc.* **7**, 2080–2089 (2012).
63. Geuder, J. et al. A non-invasive method to generate induced pluripotent stem cells from primate urine. *Sci. Rep.* **11**, 3516 (2021).
64. Rowe, R. G. & Daley, G. Q. Induced pluripotent stem cells in disease modelling and drug discovery. *Nat. Rev. Genet.* **20**, 377–388 (2019).
65. Ng, E. S. et al. Differentiation of human embryonic stem cells to HOXA⁺ hemogenic vasculature that resembles the aorta-gonad-mesonephros. *Nat. Biotechnol.* **34**, 1168–1179 (2016).
66. Sturgeon, C. M., Ditadi, A., Awong, G., Kennedy, M. & Keller, G. Wnt signaling controls the specification of definitive and primitive hematopoiesis from human pluripotent stem cells. *Nat. Biotechnol.* **32**, 554–561 (2014).
67. Dou, D. R. et al. Medial HOXA genes demarcate haematopoietic stem cell fate during human development. *Nat. Cell Biol.* **18**, 595–606 (2016).
68. Luff, S. A. et al. Identification of a retinoic acid-dependent hemogenic endothelial progenitor from human pluripotent stem cells. *Nat. Cell Biol.* **24**, 616–624 (2022).

69. Celik, H. et al. A humanized animal model predicts clonal evolution and therapeutic vulnerabilities in myeloproliferative neoplasms. *Cancer Discov.* **11**, 3126–3141 (2021).
70. Sharma, A., Sances, S., Workman, M. J. & Svendsen, C. N. Multi-lineage human iPSC-derived platforms for disease modeling and drug discovery. *Cell Stem Cell* **26**, 309–329 (2020).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any

medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

¹Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany. ²Institute of Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich, Munich, Germany. ³Institute of AI for Health, Helmholtz Zentrum München—German Research Center for Environmental Health, Neuherberg, Germany. ⁴Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna BioCenter (VBC), Vienna, Austria. ⁵Vienna BioCenter PhD Program, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna, Austria. ⁶Institute of Diabetes and Regeneration Research, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany. ⁷German Center for Diabetes Research (DZD), Neuherberg, Germany. ⁸Technical University of Munich, Munich, Germany. ⁹Anthropology and Human Genomics, Faculty of Biology, Ludwig-Maximilians-University Munich, Martinsried, Germany. ¹⁰Department of Pediatrics, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan. ¹¹Department of Biomedical Engineering (BME), Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands. ¹²German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. ¹³Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians-University Munich, Munich, Germany. ¹⁴Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria. ¹⁵Helmholtz Centre for Infection Research, Braunschweig, Germany. ¹⁶Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, Canada. ¹⁷Gene Center, Ludwig-Maximilians-University Munich, Munich, Germany. ✉ e-mail: christoph.klein@med.uni-muenchen.de

Methods

Cell culture

Human iPS cells were cultivated under feeder-free conditions on growth factor-reduced Matrigel (Corning) or Geltrex (Gibco) coated plates in mTeSRplus medium (STEMCELL Technologies). Cells were passaged every 4–5 days using ReLeSR (STEMCELL Technologies). Cells were tested routinely for mycoplasma contamination.

Differentiation of BMOs

On day –3, embryoid bodies were generated by dissociation of iPSCs into single cells with Accutase (Gibco) for 5 min at 37 °C. The dissociation reaction was stopped with mTeSRplus and cells were collected at 300g for 5 min at room temperature (RT). The cells were then resuspended in aggregation medium¹⁷ (KnockOut DMEM/F12 supplemented with 20% KnockOut Serum Replacement (Gibco), 1% L-glutamine, 1% nonessential amino acids (Gibco), 1% penicillin-streptomycin and 100 μ M β -mercaptoethanol) and counted with a hemocytometer. Next, depending on the iPSC line $1.5\text{--}4 \times 10^6$ cells were resuspended in aggregation medium supplemented with 50 μ M Y-27632 (ROCK-Inhibitor, STEMCELL Technologies) and seeded into a low-attachment petri dish. After 24 h, the medium was changed to fresh aggregation medium without ROCK-inhibitor. For the medium change, embryoid bodies were collected in 15 ml canonical tubes by gravitation (15–20 min). Mesoderm was induced on day 0 with mTeSRplus supplemented with 80 ng ml^{–1} BMP4, 4 μ M CHIR99021 (Merck Millipore) and 80 ng ml^{–1} VEGF (STEMCELL Technologies) and the plate was placed on a rocking shaker. Generally, embryoid bodies were resuspended once per day until embedding to avoid excess fusion and placed on a rocking shaker. On day 2, medium was replaced by Essential 6 medium (Gibco) supplemented with 80 ng ml^{–1} VEGF, 25 ng ml^{–1} bFGF, 50 ng ml^{–1} SCF and 2 μ M SB431542 (Selleckchem). On day 4, embryoid bodies were collected by gravitation (10–15 min) and 60–100 embryoid bodies were embedded into 1 well of a 12-well plate with 1 ml per well of a 4:1 Collagen I (Ibidi) solution–Matrigel mixture. The Collagen I solution was adapted from Wimmer et al.¹⁶ and recommendations by the manufacturers' protocol (25 μ l 10 \times DMEM, 68.75 μ l ddH₂O, 6.25 μ l 7.5% sodium bicarbonate, 117.8 μ l Hams-F12 (Gibco), 4.8 μ l HEPES (Gibco), 2.4 μ l Glutamax, 150 μ l of 5 mg ml^{–1} Collagen type I) and pH strips were used to assure pH 7.4 (1 N NaOH could otherwise be added dropwise to bring the solution to a pH of 7.4, which was almost never needed). For embedding, first a layer of 500 μ l per well of Collagen I Matrigel mixture was prepared (375 μ l Collagen I solution and 125 μ l Matrigel) and polymerized at 37 °C for 30 min to prevent embryoid bodies sinking to the bottom of the dish. Then, the embryoid bodies (in 10–15 μ l medium) were resuspended in 500 μ l per well of Collagen I Matrigel mixture and a second layer was prepared and polymerized at 37 °C for 2 h. Finally, the embedded embryoid bodies were overlaid with prewarmed Stempro-34 SFM medium (Gibco) supplemented with 80 ng ml^{–1} VEGF, 25 ng ml^{–1} bFGF, 50 ng ml^{–1} SCF and 2 μ M SB431542. On day 6, cytokines were switched to 50 ng ml^{–1} VEGF, 50 ng ml^{–1} SCF, 50 ng ml^{–1} IL-3, 50 ng ml^{–1} Flt-3L and 5 ng ml^{–1} TPO. On day 8, cytokines were changed to 25 ng ml^{–1} VEGF, 50 ng ml^{–1} SCF, 50 ng ml^{–1} IL-3, 50 ng ml^{–1} Flt-3L and 5 ng ml^{–1} TPO. On day 10, sprouted embryoid bodies were extracted from the 3D matrix with sterile dissecting tools under the laminar flow hood on an inverse light microscope. Single sprouted EBs were then transferred and further cultured in a U-bottom 96-well-low-attachment plate (PHC Europe). Thereafter, spherical organoids self-assembled and were cultured in Stempro-34 medium supplemented with 25 ng ml^{–1} VEGF, 50 ng ml^{–1} SCF, 50 ng ml^{–1} IL-3, 50 ng ml^{–1} Flt-3L and 5 ng ml^{–1} TPO and half of the medium was refreshed every 3–4 days. All cytokines were purchased from PeproTech unless indicated otherwise.

Cell lines

The human fibroblast-derived iPS cell line HMGU1 (iPSC1) was provided by the iPSC Core Facility, Institute of Stem Cell Research, Helmholtz

Center Munich (hPSCreg IFSi001-A). The VPS45 mutant (Thr224Asn) derivative iPS cell line has been described previously¹². In brief, two gRNA oligos (T1, 5'-CACCGTTTGAATTCGTCGGACAG-3'; T2, 5'-AAACCTGTCCGACGGAATTCAAAC-3') were cloned into the pSpCas9(BB)-2A-GFP (PX458, catalog no. 48138, Addgene) plasmid. The plasmids and the single-stranded oligodeoxynucleotide were cotransfected into HMGU1 iPS cells using the Amara Nucleofector II Device (program B-016, Lonza) and the Human Stem Cell Nucleofector Kit 2 (Lonza). GFP-positive cells were sorted and single colonies picked for sequencing and further expansion after confirmation of successful knock-in. The human iPS cell lines 29B5 (iPSC2) and 12C2 (iPSC5) were generated from urine samples using the CytoTune-iPS v.2.0 Sendai Reprogramming Kit (Thermo Fisher) as described previously⁶³. Human urine samples from healthy volunteers (29B5, male; 12C2, female) were obtained with written informed consent and processed anonymously. The experimental procedure was ethically approved by the responsible committee on human experimentation (20-122, Ethikkommission Ludwig-Maximilians-University (LMU) Munich). The human female PBMC-derived iPS cell line SCTi003-A (iPSC3) was purchased from STEMCELL Technologies (catalog no. 200-0511). The human male fibroblast-derived iPS cell line WTC-11 (iPSC4) was purchased via the Coriell Institute (catalog no. GM25256) from the NIGMS Human Genetic Cell Repository. Authentication and assessment of genomic integrity of cell lines were performed by the respective providers.

Mouse strains

All mice were bred, maintained, examined and euthanized in accordance with institutional animal care guidelines and ethical animal license protocols approved by the regulatory authorities. NOD.Cg-Prkdc^{scid}Il2rg^{tm1Wjl}/SzJ (NSG) mice were purchased from Charles River Laboratories. NSG mice were housed at the Institute of Molecular Biotechnology (IMBA, Vienna, Austria) under specific pathogen-free conditions in a 12 h light/dark cycle, at 20–22 °C and 45–60% humidity, with food and water ad libitum. NOD.Cg-Prkdc^{scid}H2-Ab1^{b-tm1Doi}Il2rg^{tm1Wjl}/Tg(HLA-DQA1,HLA-DQB1)1Dv/SzJ (NSG-HLA-DQ8) mice were a gift from L. Shultz (The Jackson Laboratory). NSG-HLA-DQ8 mice were bred and housed at Zentrale Versuchstierhaltung (ZVH, LMU Klinikum) under specific pathogen-free conditions in a 12 h light/dark cycle, at 20–22 °C and 45–60% humidity, with food and water ad libitum. All mouse experiments were performed according to guidelines of the Federation of European Laboratory Animal Science Association (FELASA) and the protocols were approved by the Austrian Federal Ministry of Education, Science and Research (NSG mice) and the Government of Upper Bavaria (Regierung von Oberbayern) (NSG-HLA DQ8 mice).

Mouse kidney capsule transplantation

BMOs were transplanted under the kidney capsule of 8- to 12-week-old female and male immunodeficient NSG mice^{16,28}. In brief, mice were anesthetized, and the right kidney was exposed. After a small incision was made into the renal capsule, it was carefully lifted from the functional tissue to allow for insertion of the organoid. At last, the implanted organoid was pushed an additional ~5 mm away from the incision. To test vascular connection of BMO transplants, mice were injected intravenously with 70 kDa FITC–dextran (1.25 mg in 50 μ l per mouse, Invitrogen). Transplantations were carried out under the animal license number 2022-0.429.375 according to Austrian legislation. Transplants were performed with the help of the Preclinical Phenotyping Facility at Vienna BioCenter Core Facilities (VBCF)—a member of the Vienna BioCenter (VBC), Austria.

Mouse xenotransplantation

NSG-HLA-DQ8 mice (3–4 weeks old) were preconditioned using 2.0 Gy X-ray irradiation (CP-160 Cabinet X-Radiator System). CD34⁺ sorted BMO-derived hematopoietic progenitor cells or CD34⁺ human CB cells (STEMCELL Technologies, catalog no. 7008.1) were injected

intravenously (1.0×10^5) into irradiated (2 Gy) NSG-HLA-DQ8 mice. To analyze reconstitution efficiency, peripheral blood samples were taken at 5, 8 and 10 weeks post transplantation and the presence of human hematopoietic cells was analyzed by flow cytometry. Mice were euthanized 10–12 weeks post transplantation and peripheral blood and BM cells were analyzed by flow cytometry.

Artificial thymic organoid generation

The MS5-hDLL4 cell line was established as described previously⁴⁹. In summary, MS5 cells (DMSZ, catalog no. ACC441) were transduced using a lentiviral vector encoding full-length human DLL4 cDNA. Subsequently, these cells were labeled with an anti-DLL4 antibody (Biolegend, catalog no. 346507, 1:50) and the population displaying the highest 5% DLL4 expression was isolated using FACS. Sorted cells were then cultured in DMEM/10% FCS. The stability of DLL4 expression was validated routinely through flow cytometry analysis. On the day of ATO generation, MS5-hDLL4 cells were harvested by trypsinization and resuspended in ATO medium, RPMI1640 (Gibco) supplemented with 4% B27 (Gibco), 30 μ M L-ascorbic acid 2-phosphate sesquimagnesium salt (Sigma-Aldrich), 1% penicillin/streptomycin (Gibco), 1% Glutamax (Gibco), SCF (10 ng ml⁻¹), Flt-3L (5 ng ml⁻¹) and IL-7 (5 ng ml⁻¹), all from STEMCELL Technologies. Per ATO, 1.5×10^5 MS5-hDLL4 cells were coaggregated with 1×10^4 BMO-derived sorted CD34⁺ cells and subsequently plated onto 0.4 mm Millicell transwell inserts (EMD Millipore). The inserts were placed in six-well plates, containing 1.5 ml of ATO medium per well. ATO medium was replaced completely every 3–4 days.

Flow cytometry

Flow cytometry analysis was performed on day 10, 17, 21, 24, 45 and 60 of differentiation. For flow cytometry analysis, organoids were collected and washed once with PBS. Then, organoids were dissociated enzymatically into single cells with 3U ml⁻¹ Dispase II (Gibco), 2U ml⁻¹ Liberase (Roche) and 100U ml⁻¹ DNase (STEMCELL Technologies) in PBS for 25 min at 37 °C. During the incubation period, organoids were disrupted mechanically after 10, 20 and 25 min by vigorous pipetting using a P1000 and P200 pipette. After 25 min, the dissociation reaction was stopped and single cells were washed with FACS buffer (2% FBS in PBS) and collected by centrifugation at 300g for 5 min. Cells were resuspended in FACS buffer, strained through a 70 μ m mesh, counted and incubated for 7 min with Fc block (Human True Stain FcX, Biolegend). Afterwards, cells were stained for 20 min in the dark at RT with flow cytometry antibodies listed in Supplementary Table 1. Antibody-labeled cells were washed with FACS buffer before proceeding to measuring. For the AnnexinV apoptosis detection assay, cells were washed with AnnexinV Binding Buffer (Invitrogen) and subsequently stained with fluorophore-conjugated antibodies and anti-AnnexinV. NSG mice with successful kidney transplants were euthanized 2 weeks, 3 months and 7 months after transplantation, and the femur and tibia were harvested. The intact bones were sterilized in 70% ethanol for 60 s before the bones were crushed in PBS. The BM was extracted from the crushed bones and passed through a 70 μ m filter. Following filtering, red blood cells were lysed with the BD Pharm Lyse kit (BD Biosciences, catalog no. 555899) according to the manufacturer's instructions. Properly lysed BM cells were subsequently stained with a mix of eBioscience Fixable Viability Dye eFluor 780 (Invitrogen, catalog no. 65-0865-14) and CD16/CD32 Fc blocking antibody (BD Biosciences, catalog no. 553141) in PBS for 20 min at 4 °C in the dark. After the first stain, cells were washed with FACS buffer and subsequently stained with antibodies listed in Supplementary Table 1. NSG-HLA-DQ8 mice were euthanized 10 weeks and 12 weeks after the transplantation. BM was harvested by flushing bones with PBS/2%FBS. Blood and BM were stained with antibodies listed in Supplementary Table 1 and red blood cells were lysed with the BD FACS lysing solution. Following two washes with PBS/2%FBS, blood and BM cells were filtered through a 35 μ m strainer cap before analysis. ATOs were submerged in

staining buffer (PBS/2% FBS/2 mM EDTA), disintegrated mechanically by gentle pipetting and passed through a 50 μ m strainer. Cells were subsequently labeled with antibodies listed in Supplementary Table 1. Flow cytometry measurements were performed using a BD FACS LSR Fortessa cytometer. For FACS, a BD FACS Aria cytometer was used. BD FACS DIVA software (v.9.0.1) was used to collect flow cytometry data. Appropriate gating was determined using fluorescence minus one controls (see the corresponding Supplementary Figs. 1 and 6).

Flow cytometry data analysis

Flow cytometry data were analyzed in FlowJO v.10.8. *t*-SNE analysis of flow cytometry data from three independent differentiations was performed using equal sampling of 35,000 cells from each FCS file, with 1,000 iterations, a perplexity of 30 and a learning rate of 7,350. The FlowSOM algorithm was used to create a self-organizing map with 100 clusters and 16 metaclusters. Resulting metaclusters were applied onto the *t*-SNE map.

BMO dissociation for scRNA-seq

For scRNA-seq, ten randomly selected organoids on days 17, 21 and 24 were pooled for dissociation. Organoids were then dissociated enzymatically into single cells as described above for flow cytometry analysis. After 25 min of incubation in the enzyme mixture, 0.4% bovine serum albumin (BSA)/PBS solution was added to stop the dissociation reaction, centrifuged for 5 min at 300g at 4 °C and washed again with 0.4% BSA/PBS. Next, the cell suspension was filtered through a 70 μ m mesh and counted to determine the cell number and fraction of dead cells by trypan blue staining. Cell viability was greater than 90% and final cell concentration was adjusted to 1,000 cells μ l⁻¹.

scRNA-seq library preparation and sequencing

The cell suspension was used immediately for scRNA-seq library preparation with a target recovery of 10,000 cells and loaded to a 10x Genomics Chromium Controller for Gel beads in emulsion generation and barcoding using the Chromium Single Cell 3' Reagent Kit v.3.1 Dual Index (10x Genomics) according to the manufacturer's instructions. Following cDNA synthesis, single-cell cDNA libraries were prepared. Quality control was conducted after cDNA amplification and library construction by Bioanalyzer analysis and Qubit measurement. Libraries were pooled and sequenced according to 10x Genomics recommendations on an Illumina NovaSeq6000 system with a target read depth of 50,000 reads per cell.

scRNA-seq data analysis

Sequencing data were aligned and quantified using the Cell Ranger Single-Cell Software Suite against the GRCh38 human reference genome (Ensembl release v.106). For the purpose of quality control and for downstream analysis, transcriptomic profiles were filtered according to the thresholds detailed below⁷¹. First, barcodes with fewer than 400 detected genes, more than 40,000 counts in total or with an expression of mitochondrial genes exceeding 10% of the total number of gene counts were discarded. Second, for the removal of doublets, we ran Scrublet (v.0.2.3)⁷² on each sample individually and with default parameters, filtering transcriptomic profiles with a predicted doublet score exceeding 0.2. Further, gene expression profiles were normalized to a total count number of 10,000 before log_{1p} transformation using Scanpy routines (v.1.9.1)⁷³. For the purpose of dimensional reduction, neighborhood analyses and clustering, we identified the top 4,000 highly variable genes among all samples using the corresponding Scanpy function with default parameters and performed a principal component analysis, accounting for the top 50 principal components. Cell types were annotated with reference to marker genes from published human datasets. Characteristic genes for each cell type from a one-versus-rest comparison can be found in Supplementary Table 2.

CFU assay

To determine the proliferation and differentiation ability of BMO-derived HSPCs, a CFU assay was conducted with FACS-sorted CD45⁺ CD11b[−] CD34⁺ cells. The assay was performed in triplicate according to the manufacturer's protocol. Briefly, sorted cells were diluted in IMDM (Gibco) medium containing 1% penicillin-streptomycin. Diluted cells were added to complete MethoCult H4435 enriched medium (STEMCELL Technologies). A total of 1,000 cells were seeded per 35 mm dish and CFUs were counted on day 14 using an inverted light microscope. Correct assignment of colony lineage was verified by May–Gruenwald–Giemsa staining of sampled colonies.

Trilineage MSPC differentiation assay

BMO-derived sorted MSPCs were seeded in six-well plates at a density of 4×10^3 cells cm^{−2}. For expansion, cells were cultured in MesenCult basal medium. When cells reached approximately 90% confluence, osteogenic and adipogenic differentiation was induced as followed: adipogenic differentiation was induced with MesenCult adipogenic differentiation medium, and medium was refreshed every 3 days. On day 28 of differentiation, cells were fixed in 10% formalin for 30 mins at RT, and lipid droplets were visualized by Oil-red-O staining. Osteogenic differentiation was induced using MesenCult osteogenic differentiation medium. Cells were maintained for 28 days, and medium was refreshed every 3–4 days. On day 28, cells were fixed in 10% formalin for 30 mins at RT and calcium deposits were visualized by Alizarin Red-S staining. A 3D pellet differentiation system was used for chondrogenic differentiation: 5×10^5 MSPCs were resuspended in MesenCult-ACF chondrogenic differentiation medium and transferred to a 15 ml canonical tube. Cells were pelleted at 300g for 5 min and the lid was loosened to allow gas exchange. Pellets were maintained for 21 days, and medium was refreshed every 3 days. On day 21 chondrogenic pellets were fixed in 10% formalin for 30 min at RT. Preparation of paraffin slides and histological analysis with Alcian-blue stain was performed according to standard protocols. Medium and differentiation kits were purchased from STEMCELL Technologies.

Modeling inflammation

To evaluate emergency granulopoiesis in the BMOs, organoids were placed in a 96-well round bottom plate in triplicate. LPS ($1 \mu\text{g ml}^{-1}$, Sigma-Aldrich) or heat-killed *L. monocytogenes* ($1 \times 10^9 \text{ ml}^{-1}$, InvivoGen) were added into the cell culture medium for 4 h and 24 h. BMOs were harvested to assess emergency granulopoiesis using flow cytometry after 24 h, and supernatants were used to assess the production of G-CSF (R&D) and pro-inflammatory cytokines IL-6 (R&D) and IL-8 (R&D) at indicated timepoints. Enzyme-linked immunosorbent assays were performed according to manufacturer's protocols.

Immunofluorescence

Sprouted EBs of day 10 were fixed with 4% paraformaldehyde (PFA) for 20 min and organoids from day 17 onwards were washed with PBS and fixed with 4% PFA for 1 h at RT. Afterwards, they were permeabilized and incubated in blocking buffer (3% FBS, 1% BSA, 0.5% Triton X-100 and 0.5% Tween) for 2 h at RT on a shaker. Incubation with primary antibodies diluted in blocking buffer was done overnight at 4°C on a shaker. For immunofluorescence analysis of xenotransplants following dextran injection, kidneys were fixed in 10% neutral buffered formalin, cryo-embedded (Tissue-Tek OCT compound, Sakura) and cryosectioned into 14 μm sections. The following primary antibodies and dilutions were used: anti-CD31 (R&D Systems, catalog no. AF806, 1:20), anti-CD34 (Abcam, catalog no. ab81289, 1:100), anti-CD41 (Abcam, catalog no. ab134131, 1:200), anti-CD45 (Abcam, catalog no. ab10558, 1:350), anti-CD45 AlexaFluor 647 (Biolegend, catalog no. 304018, 1:20), anti-Collagen II (Abcam, catalog no. ab34712, 1:100), anti-Collagen IV (Sigma, catalog no. AB769, 1:200), anti-CXCL12/SDF-1 (R&D Systems, catalog no. MAB350, 1:30), anti-LepR AlexaFluor

647 (BD, catalog no. 564376, 1:30), anti-MPO (Abcam, catalog no. ab25989, 1:250), anti-Nestin (R&D Systems, catalog no. MAB1259, 1:20), anti-NGFR/CD271 (Sigma, catalog no. HPA004765, 1:500), anti-PDGFR β (Cell Signaling, catalog no. 3169 S, 1:100), anti-PRRX1 (Sigma, catalog no. ZRB2165, 1:50), anti-RUNX1/AML-1 (Cell Signaling, catalog no. 4336T, 1:200), anti-S100A8/A9 (Abcam, catalog no. ab17050, 1:200) and anti-SMA (Abcam, catalog no. ab5694, 1:200). The BMOs were then washed three times with PBST (0.05% Tween in PBS) followed by a 2-h RT incubation with corresponding secondary antibodies diluted 1:300 in blocking buffer. Secondary antibodies from Invitrogen were: AlexaFluor 488 donkey anti-goat (catalog no. A11055), AlexaFluor 488 donkey anti-mouse (catalog no. A21202), AlexaFluor 488 donkey anti-rabbit (catalog no. A21200), AlexaFluor 488 donkey anti-sheep (catalog no. A11015), AlexaFluor 488 goat anti-rabbit (catalog no. A11034), AlexaFluor 568 donkey anti-rabbit (catalog no. A10042), AlexaFluor 594 goat anti-mouse (catalog no. A11032), AlexaFluor 594 goat anti-rabbit (catalog no. A11012) AlexaFluor 633 donkey anti-sheep (catalog no. A21100) and AlexaFluor 633 goat anti-mouse (catalog no. A21052). Finally, BMOs were stained with 4,6-diamidino-2-phenylindole for 15 min at RT and washed three times for 10 min with washing buffer. The stained BMOs were then mounted into wells of a prepared mounting system with fluorescence mounting medium (DAKO). This system was comprised of a 1.0 mm iSpacer (SunJin Laboratory) attached to a 22 \times 50mm no. 1.5 coverslip, with double-sided tape on the top side. Once mounted, another coverslip was placed on top and the edges were sealed. For optical clearing, BMOs were placed after immunolabeling into one well of the mounting set-up and 65 μl of RapiClear v.1.47 (SunJin Laboratory) was added. After 10 min, the top coverslip (22 \times 50mm no. 1.5) was added, and light pressure was applied to seal the sample. Slides were stored in the dark at 4°C until imaging. Each antibody staining was performed a minimum of three times in independent organoids. Secondary antibody controls were run in parallel to assess unspecific binding or background fluorescence signal.

Confocal microscopy

Confocal laser scanning microscopy of organoids was performed with either an inverted Zeiss LSM800 microscope or an inverted Leica SP8 3x microscope. Overview images of organoids were acquired through tile scans using a $\times 20/0.8$ M27 air objective (Zeiss) or a $\times 25/0.95$ water immersion objective (Leica), utilizing optical zoom for enhanced visualization of cellular architecture. Specific cellular structures were imaged with a $\times 63/1.4$ Oil DIC M27 objective (Zeiss) with immersion oil (Immersol 518F, Zeiss). All fluorescent targets were recorded in individual spectral channels and acquired in sequential mode. Spectral channel settings were chosen to optimize intensity while limiting bleed-through and background noise. A series of x-y-z images along large-tiled areas was acquired to represent whole organoids in reconstructed 3D z-projections. Z-stacks were sampled with ax-y-z-resolution for proper Nyquist sampling over a range of depths. All image acquisition was accomplished using Zeiss ZEN blue software v.2.6 or Leica Application Suite (LAS) X (v.3.8). Image processing was performed with FIJI, ZEN blue (v.2.6), LASX (v.3.8) and Imaris (v.9.7.2) software packages, with similar processing settings applied for respective negative controls.

Two-photon microscopy

Two-photon-microscopy was performed at the Core Facility Bioimaging of the Biomedical Center of the LMU with a Leica SP8 MP DIVE microscope. The microscope has an upright DM8 stand and a motorized Scientifica stage. A FLUOTAR $\times 16/0.60$ IMM objective was used with Leica immersion liquid Type G. A Spectra Physics Insight $\times 3$ laser delivered 925, 1,045, 760 and 1,250 nm as excitation wavelengths. Recording was in a stack sequential manner, spectral detection of hybrid detectors in the non-descanned DIVE module was set to 500–550 nm, 570–610 nm, 400–480 nm and 650–700 nm. Images were recorded

with $1,024 \times 1,024$ pixels with a pixel size of 750–900 nm (variable zoom) at 400 lines per second and a z-distance of 5 μm . Z-dimensions ranged from 515 μm to 845 μm and are indicated in figure legends. Image acquisition was accomplished using LASX (v.3.8). Image processing was performed with Imaris (v.9.7.2) software packages, with similar processing settings applied for respective negative controls.

Image rendering and analysis

The 3D reconstruction and surface rendering of confocal and two-photon images were performed using the Imaris v.9.7.2. software package (Bitplane) with .ims as standard file format. Large confocal tiles scans were stitched with the Imaris v.9.7.2 Stitcher software (Bitplane) on computer at the Bioimaging core facility with 256 GB RAM, Intel Xeon CPU E5-2643 v.4 @ 3.4 GHz, 31-inch monitor with $4,096 \times 2,160$ pixels and a Nvidia Quadro RTX 5000 GPU with 16 GB GDDR6. Parallel-processing CUDA cores, 3,072; Tensor cores, 384; RT cores, 48.

Angiotool

Three z-stacks of tile scans of whole-mount organoids were processed via the Angiotool interface²⁷ to quantify total number of junctions, vessel area and branching index. Branching index is calculated as vessel area divided by junctions.

Immunohistochemistry

Organoids were fixed with 4% PFA for 1 h at RT, washed with PBS and embedded in paraffin. Organoid sections of 1.5 μm thickness were generated using the Leica RM2245 microtome (Leica). Organoid sections were stained with H/E or Gomori using standard protocols or used for immunohistochemistry staining. After antigen retrieval, slides were incubated with CD34 (Sigma-Aldrich, catalog no. QEBnd-10; 1:100) or MPO (DAKO/Agilent, catalog no. A0298, 1:400) for 1 h. Detection was carried out with ImmPress anti-rabbit IgG polymer kit (Vector Laboratories) or MACH 3 Mouse HRP Polymer detection (Biacore Medical), respectively, according to the manufacturer's protocol. Images were acquired on a Carl Zeiss Axioplan 2 or a Leica DM 2000 microscope. Reticulin staining was assessed by an experienced hematopathologist.

Histology of xenotransplants

Mouse kidneys were harvested, cleared from residual fat tissue and fixed overnight by immersion in 10% neutral buffered formalin. They were processed with an automated tissue processor (Donatello I, DIA-PATH), embedded in paraffin, sectioned at a thickness of 2 μm with a standard rotary microtome (Microm HM 355, Thermo Fisher Scientific), collected on glass slides and dried in the oven at 50 °C overnight. Sections were stained with H/E or hCD31 antibody (R&D, catalog no. AF806) on an automated staining platform (Eprelia Gemini AS Automated Slide Stainer). Whole-slide images were prepared using the Panoramic FLASH 250 III whole-slide scanner (3D Histech) with the $\times 40/0.95$ plan apochromat objective and Adimec Quartz Q12A180 camera for bright-field and a pco.edge 4.2 4MP camera for fluorescent samples. Representative images were acquired from whole-slide images with the Case Viewer Software (3D Histech). Histology of xenotransplants was performed by the Histology Facility at VBCF.

Cytospins

Target populations were FACS-sorted into Eppendorf tubes containing FACS buffer or picked colonies from the CFU assay were centrifuged in PBS for 10 min. Next, around 1×10^4 cells were centrifuged at 500 rpm at RT for 5 min onto cytoslides (Tharmac) using a Cellspin I Cytocentrifuge (Tharmac) and air-dried overnight. Slides were stained with May–Gruenwald solution (Merck) for 2 min, followed by Giemsa azur-eosin-methylene blue solution (Merck) diluted 1:20 in Sorensen's buffer for 17 min. Slides were viewed using a Leica DM 2000 microscope with a $\times 100$ objective.

Electron microscopy

Two randomly picked organoids were fixed using a mixture of 2% glutaraldehyde (Agar Scientific) and 2% PFA (Electron Microscopy Sciences) in 0.1 mol l⁻¹ sodium cacodylate buffer, pH 7.2, for 4 h at RT. Fixative was then removed and organoids were stored in storage buffer at 4 °C overnight. The next day, samples were rinsed three times for 10 min with the same buffer and postfixed in 2% osmium tetroxide (Agar Scientific) in 0.1 mol l⁻¹ sodium cacodylate buffer. After another three washing steps the organoids were dehydrated in a graded series of acetone and embedded in Agar 100 resin (Agar Scientific). Subsequently, 70-nm sections were cut and poststained with 2% uranyl acetate and Reynolds lead citrate (Delta Microscopies). Micrographs of representative sections from two different organoids were recorded on an FEI Morgagni 268D (FEI) operated at 80 keV, equipped with a Mega View III CCD camera (Olympus-SIS) and in a Tecnai G2 20 operated at 200 keV (FEI), using an Eagle 4k HS camera. Electron microscopy studies were performed by the Electron Microscopy Facility at VBCF.

Data visualization, statistical analysis and reproducibility

Data visualization and statistical analysis was done in GraphPad Prism v.9. Flow cytometry data were analyzed in FlowJo v.10. Confocal images were processed and analyzed in Fiji, ZEN blue edition v.2.6 and Imaris v.9.7.2. The data are presented as mean \pm s.e.m. For statistical analysis, a two-tailed unpaired *t*-test or a two-way analysis of variance followed by Sidak's multiple comparison were performed. The differentiation protocol was replicated by five different investigators (S.F.-W., I.G., S.D.F., M.K. and P.C.) using iPSC1–5 and at least four different batches of Matrigel (lot numbers 0048007, 1013002, 1032003, 2067001) with similar results.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The scRNA-seq data presented in this study are available and can be accessed online for interactive exploration via the CellxGene portal explorer (cellxgene.cziscience.com). Raw and processed sequencing data are deposited at the Gene Expression Omnibus (GEO) repository under the accession code ([GSE249005](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE249005)). Additionally, Scanpy h5ad objects of the preprocessed scRNA-seq data are available for download via the CellxGene portal explorer. Source data are provided with this paper.

Code availability

No custom code was used for the analysis presented in this study. Single-cell sequencing data were processed and analyzed using publicly available software packages.

References

- Luecken, M. D. & Theis, F. J. Current best practices in single-cell RNA-seq analysis: a tutorial. *Mol. Syst. Biol.* **15**, e8746 (2019).
- Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. *Cell Syst.* **8**, 281–291.e9 (2019).
- Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. *Genome Biol.* **19**, 15 (2018).

Acknowledgements

We are grateful to all team members of our laboratory and core facilities for stimulating discussion and help, in particular M. Tatematsu, M. Rohlf and J. Bibus. We would like to thank S. Dietzel and A. Thomae from the Core Facility Bioimaging of the Biomedical Center of the LMU for excellent technical assistance. We thank N. Drexler and T. Heuser from the Electron Microscopy Facility and M. Grivej from the Histology Facility at VBCF, which acknowledges

funding from the Austrian Federal Ministry of Education, Science and Research and the City of Vienna. We thank M. Drukker for providing the HMGU1 iPS cell line. We thank W. Enard for providing the 29B5 and 12C2 iPS cell lines. We thank L. Shultz (The Jackson Laboratory) for providing NSG-HLA-DQ8 mice. We would like to thank G. Piontek at the Institute of Pathology, LMU Munich and T. Walzthoeni at the Core Facility Genomics, Helmholtz Munich for technical assistance. This work has been supported by the Reinhard Frank-Stiftung, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation; SFB914/A08, TRR332/B01, CRC1123/Z1, INST 86/1909-1, INST409/150-1FUGG, EN 1093/5-1, project number 458247426), the German Center for Infection Research (DZIF, TTU07.820), the Else Kröner-Fresenius-Stiftung, the Hector Foundation, the Leona M. and Harry B. Helmsley Charitable Trust, the VEO-IBD-Consortium and the National Institute of Health (RC2 VEO-IBD 5RC2DK122532-02), as well as institutional funds by the Dr. von Hauner Children's Hospital. C.M. has received funding from the European Research Council (ERC) and the European Union's Horizon 2020 research and innovation program (grant agreement no. 8664111) and acknowledges support from the Hightech Agenda Bayern. The laboratory of J.M.P. received funding from the Austrian Academy of Sciences, the Medical University of Vienna, the Fundacio La Marato de TV3 (202125-31), the T. von Zastrow foundation, the Canada 150 Research Chairs Program F18-01336, the Allen Distinguished Investigator program, the Leducq Foundation (Transatlantic Network of Excellence grant 'ReVAMP—Recalibrating Mechanotransduction in Vascular Malformations', 21CVD03), the Diamond-Blackfan-Anemia Fundraising (dbaexperiment.org) and the Innovative Medicines Initiative2 Joint Undertaking (no. 101005026). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA (European Federation of Pharmaceutical Industries and Associations). J.M.P. also gratefully acknowledges funding by the German Federal Ministry of Education and Research (BMBF) under the project 'Microbial Stargazing—Erforschung von Resilienzmechanismen von Mikroben und Menschen' (Ref. 01KX2324). Schemes in Figs. 1–6 and Extended Data Figs. 3 and 4 were created with BioRender.com.

Author contributions

S.F.-W. developed the human BMOs and performed the in vitro organoid experiments together with I.G., S.D.F., M.K. and P.C. M.B. and S.F.-W. performed scRNA-seq data analysis under the

supervision of C.M. K.S. and G.J. performed kidney transplantation experiments in mice under the supervision of J.M.P. D.I. performed xenotransplantation experiments and Y.L. performed inflammation modeling experiments under the supervision of D.K. B.z.P. and D.P. performed ATO experiments. J.G. generated the 29B5 and 12C2 iPS cell lines. Y.M. generated the VPS45-KI iPS cell line. R.C. helped with flow cytometry. M.R. performed histological analysis of organoids. M.S. and P.C. prepared single-cell libraries. R.T.A.M. partially supervised S.F. and helped with microscopy. M.I.L. and M.B. helped write the manuscript. C.K. supervised the project, monitored the experiments and acquired funding. S.F.-W. and C.K. coordinated the project and wrote the manuscript. All authors read and approved the final manuscript.

Competing interests

S.F.-W., I.G. and C.K. are inventors on a patent application for the subject matter of this publication (WO2023/194370A1). J.M.P. is inventor on a patent covering blood vessel organoids (US20200199541A1) and founder, shareholder and chairman of the scientific advisory board of Angios Biotech, a company that develops blood vessel organoids for human use. All other authors declare no competing interests.

Additional information


Extended data is available for this paper at <https://doi.org/10.1038/s41592-024-02172-2>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41592-024-02172-2>.

Correspondence and requests for materials should be addressed to Christoph Klein.


Peer review information *Nature Methods* thanks Hitoshi Takizawa and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Madhura Mukhopadhyay, in collaboration with the *Nature Methods* team.

Reprints and permissions information is available at www.nature.com/reprints.




Extended Data Fig. 1 | Flow cytometry analysis, morphology and cell type frequencies of BMOs across various iPSC lines. a) Gating strategy for flow cytometric analysis of dissociated BMOs. **b)** Quantification of cell type frequencies for main fractions of iPSC1-BMOs day 10-60; $n = 5$ independent differentiations for day 17, 21, $n = 3$ independent differentiations for day 10, 24, 45, 60. **c)** Quantification of cell type frequencies of HSPCs and MSPCs of iPSC1-BMOs day 10-60; $n = 5$ independent differentiations for day 17, 21, $n = 3$ independent

differentiations for day 10, 24, 45, 60. **d)** Bright field images of BMOs generated from iPSC2-5 at day 17. **e)** Mean diameter of iPSC1-5 derived BMOs on day 17 of differentiation for $n = 24$ (iPSC1 and 2), $n = 20$ (iPSC3 and 4) and $n = 17$ (iPSC5) organoids. Bar indicates mean value. **f)** Quantification of cell type frequencies of iPSC2-5-BMOs on day 17, iPSC2 $n = 5$ independent differentiations; iPSC3, 4, 5 $n = 3$ independent differentiations. Data in **b)**, **c)** and **f)** are presented as mean values \pm s.e.m. Scale bar in **d)** 500 μm .



Extended Data Fig. 2 | Complex BMO architecture across various iPSC cell lines. **a)** Analysis of representative mature whole-mount organoid (iPSC2-5) stained with indicated antibodies using two-photon microscopy; $n = 3$ independent experiments. **b)** Representative surface rendering of CD45, CD271 and CD31 expressing cells for volume quantification of $n = 5$ organoids (iPSC1-5).

c) Quantification of indicated cell types within BMOs ($n = 5$ organoids) derived from iPSC1-5. **d)** Coloring of CD45+ cells based on distance to image border. **e)** Quantification of the spatial CD45+ distribution as measured by distance to image border in XYZ dimension for $n = 647$ (iPSC1), 822 (iPSC2), 1119 (iPSC3), 2761 (iPSC4) and 1494 (iPSC5) CD45+ surface objects. Scale bars in a), b), d) 100 μm .




Extended Data Fig. 3 | See next page for caption.

Extended Data Fig. 3 | Characterization of mesenchymal and vascular structures.


a) Confocal images of immunostaining of CD31 (endothelial cells) and PDGFR β (pericytes) in a BMO; related to Fig. 2a. **b)** Analysis of CXCL12-expressing pericytes by confocal microscopy as shown in merged image in Fig. 2e. **c)** Analysis of immunostaining of CD31, CD45 and Nestin in the whole organoid by two-photon-microscopy. Z-dimension 845 μm . **a)–c)** Representative images from $n = 3$ independent experiments. **d)** Analysis of LepR expression on CD271 $^{+}$ mesenchymal cells by flow cytometry. **e)** Quantitative analysis of CD271 $^{+}$ cells expressing LepR; $n = 3$ independent differentiations. Data are presented as mean value \pm SEM. **f)** Z-projection of whole-mount organoid. Arrows indicate enveloped structure enclosing the whole organoid. **g)** Immunohistochemical staining of paraffin embedded organoid section for CD34. **h)** Interconnectivity of vascular-like network computed with Angiotool. **f)–k)** Representative images from $n = 3$ independent experiments. **i)** TEM image analysis of endothelial cells connected by tight junctions (TJ), Weibel-Palade body (asterisk) and pericyte

(P). Representative micrograph of sections from $n = 2$ independent experiments. **j)** Hematoxylin-Eosin (HE) staining of different regions of histological sections with morphologically hematopoietic cells within a lumen of vessel-like structures. Representative images from $n = 3$ independent experiments. **k)** Analysis of organoid sections showing endothelial cells (E) encompassing round cells resembling myeloid cells (M) by TEM. Representative micrograph of sections from $n = 2$ independent experiments. **l)** Orthogonal 2D z-projection of vessel structure of bottom image in Fig. 2b) in xz and yz direction. Note lumen formation indicated by arrows. **m)** Horizontal view of representative z-stack of BMO by confocal microscopy related to Fig. 1h and surface rendering for CD31 and CD45. Still of Supplementary Video 5. **n)** Surface rendering of confocal imaging showing CD31 $^{+}$ vessels lined by Nestin expressing cells and enclosing CD45 $^{+}$ hematopoietic cells inside the vessel. Still of Supplementary Video 6. Scale bars **a), c), f), h)** 100 μm , **b)** 50 μm , **g), 200 μm , i), k) 2 μm , j), l) 20 μm , m), n) 10 μm .**



Extended Data Fig. 4 | Functional properties of MSCs and BMO kidney capsule xenotransplantation to test vascular functionality. **a)** Scheme representing the trilineage differentiation assay of FACS-sorted BMO-derived MSCs. MSCs were cultured in either osteogenic, adipogenic or chondrogenic differentiation medium for at least 21 days. **b)** Osteogenic, adipogenic and chondrogenic differentiation was visualized by Alizarin Red-S, Oil-red-O or Alcian-Blue staining, respectively; $n = 4$ independent experiments with iPSC line 1 and 2. **c)** Scheme representing xenotransplantation of BMOs under the kidney capsule of NSG mice and follow-up analysis. **d)** Macroscopic morphology of xenotransplants attached to kidney and untransplanted control kidney after 2 weeks, 3 months and 7 months showing further growth *in vivo*. **e)**

Hematoxylin-Eosin-stained section of paraffin-embedded organoid 3 months after transplantation, $n = 3$ mice. **f)** Immunohistochemistry of human-specific CD31 antibody to determine BMO origin of vessels at 3 months, $n = 3$ mice. **g)** Representative plot of flow cytometric analysis for presence of human CD45⁺ cells within murine bone marrow in transplanted mice and control mice. Frequency of hCD45⁺ cells in **h)** bone marrow and **i)** blood of transplanted mice at indicated time points after transplantations, bone marrow: 2 weeks $n = 3$ mice, 3 months $n = 5$ mice, 7 months $n = 2$ mice; blood: 2 weeks $n = 4$ mice, 8 weeks $n = 5$ mice 3 months $n = 4$ mice. **j)** Immunofluorescence analysis of BMO transplants after intravenous injection of FITC-labeled dextran, $n = 3$ mice. Scale bars in b), e), f) 50 μm , j) left 50 μm , right 20 μm .



Extended Data Fig. 5 | See next page for caption.

Extended Data Fig. 5 | Identification of lymphoid progenitor cells and megakaryocyte-like cells and analysis of mesenchymal and endothelial cell population. **a)** UMAP projection of LMPP marker genes; LMPP, lymphoid-primed multipotent progenitors. **b)** UMAP projection of ELP marker genes; ELP, early lymphoid progenitor. **c)** CD10 and IL7R expression on a CD34⁺CD90^{mid}CD45⁺ subset by flow cytometry. **d)** Quantitative analysis of CD10 and IL7R expression on a CD34⁺CD90^{mid}CD45⁺ subset for $n = 4$ independent experiments. Data are shown as mean \pm SEM. **e)** Detection of CD41⁺CD61⁺CD42⁺ cells by flow cytometry of dissociated BMOs. **f)** Analysis of Giemsa-stained cytopsin preparations of sorted CD41⁺CD61⁺CD42⁺ cells, $n = 2$ independent experiments. **g)** Immunofluorescence analysis of multinucleated CD41⁺ cell within the BMO, $n = 3$ independent experiments. **h)** TEM imaging analysis of organoid

section displaying a large cell with a characteristic demarcation membrane system (DMS). Representative micrograph of sections from $n = 2$ independent experiments. **i)** UMAP projection of mesenchymal niche marker gene expression. **j)** Alcian blue positive spots in sections of BMOs at day 45 of differentiation. **k)** Rare Collagen II expressing cells in the BMO at day 21 of differentiation. **l)** Analysis of nuclear expression of PRRX1 in mesenchymal cells by confocal microscopy. **j)–l)** $n = 3$ independent experiments. **m)** Representative histogram for expression of arterial surface markers DLL4 and CXCR4 on CD31⁺ endothelial cells and **n)** quantitative frequencies of DLL4 and CXCR4 on CD31⁺ endothelial cells for $n = 3$ independent experiments. Data are presented as mean values \pm s.e.m. Scale bars in f), g) 20 μ m, h) 2 μ m, j), k), l) 20 μ m.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed
<input type="checkbox"/>	<input checked="" type="checkbox"/> The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement
<input type="checkbox"/>	<input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
<input type="checkbox"/>	<input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided <i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>
<input type="checkbox"/>	<input checked="" type="checkbox"/> A description of all covariates tested
<input type="checkbox"/>	<input checked="" type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
<input type="checkbox"/>	<input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
<input type="checkbox"/>	<input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
<input checked="" type="checkbox"/>	<input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
<input checked="" type="checkbox"/>	<input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
<input checked="" type="checkbox"/>	<input type="checkbox"/> Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	ZEN v2.6. blue edition software (Zeiss) and Leica Application Suite (LAS) X (Leica) software was used for confocal microscopy, Leica Application Suite (LAS) X (Leica) software was used for recording of two-photon microscopy studies. FACS DIVA software v9.0.1 (BD) was used to collect flow cytometry data.
Data analysis	Data visualization and statistical analysis was done in GraphPad Prism v9. Flow cytometry data were analysed in FlowJo v10. Confocal images were processed and analysed in Fiji, ZEN v2.6. blue edition and Imaris v9.7.2 (Bitplane). Two-photon images were processed and analysed in Imaris v9.7.2 (Bitplane). The Scanpy package (version 1.9.1) was used for the analysis of scRNAseq data. Scrublet (version 0.2.3) was used for the removal of doublets. Any data filtering steps are detailed in the manuscript. Scanpy h5ad objects of the preprocessed scRNAseq data is available for exploration and download via cellxgene.cziscience.com . Code Availability statement: No custom code was used for the analysis presented in this study. Single-cell sequencing data were processed and analysed using publicly available software packages.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The single cell RNA sequencing data presented in this study are available and can be accessed online for interactive exploration via the CellxGene portal explorer (cellxgene.cziscience.com). Raw and processed sequencing data are deposited at Gene Expression Omnibus (GEO) repository under the accession code GSE249005. Additionally, Scanpy h5ad objects of the preprocessed scRNAseq data are available for download via the CellxGene portal explorer.

Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	Two human iPSC lines, generated from urin samples were used, one male and one female.
Population characteristics	Students from Munich, Germany.
Recruitment	Students were recruited from graduate and under-graduate students of biology in Munich, Germany. Informed consent was obtained from all volunteers and urine samples were processed anonymously, but separately for males and females.
Ethics oversight	Ethikkommission Ludwig-Maximilians-University Munich, Germany (20-122).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No statistical methods were used to predetermine sample size. Samples sizes were based on determining sufficient replication to account for biological variation. For statistical analysis between different treatment groups or genotypes at least three different biological replicates were analyzed.
Data exclusions	No data were excluded in this study except standard removal of low quality single cells for downstream analysis of scRNA-seq data as described in the Methods section.
Replication	All experiments in this study were independently biologically replicated and all attempts of replication were successful. The differentiation protocol was replicated by five different investigators (S.F.-W., I.G., S.D.F., M.K., P.C.) using five different iPS cell lines (iPSC#1-#5) and at least four different batches of Matrigel (lot numbers: 0048007, 1013002, 1032003, 2067001) with similar results.
Randomization	Organoids were randomly selected from organoid batches for subsequent experiments.
Blinding	Investigators were not blinded during experiments. Blinding was not applicable, since the same investigators performed data collection and analysis.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used

Antibodies used for flow cytometry are included in Supplementary Table 1 and listed below.

Antibody, fluorophore, clone, catalog number, manufacturer, dilution (all antibodies anti-human, except m indicates anti-mouse):

CD3 PacificBlue SK7 344824 BioLegend 1:100
 CD3 BV650 UCHT1 563852 BD 1:100
 CD4 BV480 RPA-T4 7456541 BD 1:100
 CD5 APC UCHT2 555355 BD 1:50
 CD7 BB700 M-T701 566488 BD 1:100
 CD8 PE QA18A37 303804 BioLegend 1:100
 CD10 PE HI10A 555375 BD 1:30
 CD11b BV605 ICRF44 562721 BD 1:100
 CD11b BB515 ICRF44 564517 BD 1:100
 CD14 APC-Fire 750 M5E2 301854 BioLegend 1:100
 CD16 PE-Cy7 3G8 557744 BD 1:100
 CD19 R718 SJ25C1 566946 BD 1:50
 CD20 PE-Cy7 2H7 560735 BD 1:100
 CD24 PE-Dazzle 594 ML5 311134 BioLegend 1:100
 CD31 APC WM59 303116 BioLegend 1:100
 CD31 PE-Cy7 WM59 303118 BioLegend 1:100
 CD33 PE HIM3-4 12-0339-42 Invitrogen 1:100
 CD34 PE-Dazzle 594 581 343534 BioLegend 1:100
 CD34 BV421 581 562577 BD 1:100
 CD35 BV480 E11 746503 BD 1:100
 CD41 PE HIP8 557297 BD 1:30
 CD42 APC HIP1 551061 BD 1:30
 CD45 FITC HI30 304006 BioLegend 1:50
 CD45 APC-R700 HI30 566041 BD 1:100
 CD45 APC HI30 304012 BioLegend 1:50
 CD49d PE 9F10 555503 BD 1:100
 CD49d BV421 9F10 304322 BioLegend 1:100
 CD56 BUV496 NCAM16.2 750479 BD 1:100
 CD61 FITC VIPL2 555753 BD 1:30
 CD73 PE-Cy7 AD2 561258 BD 1:100
 CD90 BV711 5E10 328140 BioLegend 1:100
 CD101 BV605 V7.1 747548 BD 1:100
 CD105 BV421 SN6h 800510 BioLegend 1:100
 CD117 BB700 YB5.B8 566548 BD 1:30
 CD127 (IL7R) APC A019D5 351316 BioLegend 1:30
 CD184 (CXCR4) BV480 12G5 746621 BD 1:50
 CD271 PE ME20.4 345106 BioLegend 1:300
 CD295 (LepR) AF647 52263 564376 BD 1:50
 DLL4 APC MHD4-46 346507 BioLegend 1:50
 Siglec8 APC 7C9 347106 BioLegend 1:100
 TCRab PE-Cy7 IP26 306720 BioLegend 1:50
 TCRcd BV421 B1 562560 BD 1:30
 mCD29 PE-Cy5 HMB1-1 102219 BioLegend 1:100
 mCD45 FITC 30-F11 103108 BioLegend 1:100
 mCD45 PE 30-F11 12-0451-83 Thermo Fisher 1:100
 Annexin V APC 17-8007-74 Thermo Fisher 1:50
 Fixable viability stain Red780 565388 BD 1:400

The following anti-human primary antibodies and dilutions were used for immunofluorescence:

anti-CD31/PECAM1 (R&D Systems AF806, 1:20)
 anti-CD34 (abcam ab81289, clone EP373Y, 1:100)
 anti-CD41 (abcam ab134131, clone EPR4330, 1:200)
 anti-CD45 (abcam ab10558, 1:350)
 anti-CD45 Alexa Fluor 647 (Biolegend 304018, clone HI30, 1:15)
 anti-Collagen II (abcam, ab34712, 1:100)
 anti-Collagen IV (Sigma AB769, 1:200)
 anti-CXCL12/SDF-1 (R&D Systems MAB350, clone 79018, 1:30)

anti-LepR Alexa Fluor 647 (BD, 564376, clone 52263, 1:30)
 anti-MPO (abcam ab25989, clone 2C7, 1:250)
 anti-Nestin (R&D Systems MAB1259, clone 196908, 1:20)
 anti-NGFR/CD271 (Sigma HPA004765, 1:500)
 anti-PDGFR β (Cell Signaling 3169S, clone 28E1, 1:100)
 anti-PRRX1 (Sigma, ZRB2165, 1:50)
 anti-RUNX1/AML-1 (Cell Signaling 4336T, clone D33G6, 1:200)
 anti S100A8/A9 (abcam ab17050, clone 27E10, 1:200)
 anti-SMA (abcam ab5694, 1:200).

Secondary antibodies from Invitrogen were diluted 1:300: AlexaFluor 488 donkey anti-goat (A11055), AlexaFluor 488 donkey anti-mouse (A21202), AlexaFluor 488 donkey anti-rabbit (A21200), AlexaFluor 488 donkey anti-sheep (A11015), AlexaFluor 488 goat anti-rabbit (A11034), AlexaFluor 568 donkey anti-rabbit (A10042), AlexaFluor 594 goat anti-mouse (A11032), AlexaFluor 594 goat anti-rabbit (A11012) AlexaFluor 633 donkey anti-sheep (A21100), AlexaFluor 633 goat anti-mouse (A21052).

For immunohistochemistry the following antibodies were used: CD34 (Sigma-Aldrich, QEBnd-10; 1:100) or MPO (DAKO/Agilent, A0298, 1:400).

Validation

All antibodies used in this study are commercially available and have been validated for the application by the manufacturer or have been previously validated in other publications:

anti-CD31/PECAM1 (R&D Systems AF806, 1:20), https://www.rndsystems.com/products/human-cd31-pecam-1-antibody_af806
 anti-CD34 (abcam ab81289, clone EP373Y, 1:100), <https://www.abcam.com/products/primary-antibodies/cd34-antibody-ep373y-ab81289.html>
 anti-CD41 (abcam ab134131, clone EPR4330, 1:200), <https://www.abcam.com/products/primary-antibodies/cd41-antibody-epr4330-ab134131.html>
 anti-CD45 (abcam ab10558, 1:350), <https://www.abcam.com/products/primary-antibodies/cd45-antibody-ab10558.html>
 anti-CD45 Alexa Fluor 647 (Biolegend 304018, clone HI30, 1:15)
 anti-Collagen II (abcam, ab34712, 1:100), <https://www.abcam.com/products/primary-antibodies/collagen-ii-antibody-ab34712.html>
 anti-Collagen IV (Sigma AB769, 1:200), <https://www.sigmaaldrich.com/DE/de/product/mm/ab769>
 anti-CXCL12/SDF-1 (R&D Systems MAB350, clone 79018, 1:30), https://www.rndsystems.com/products/human-mouse-cxcl12-sdf-1-antibody-79018_mab350
 anti-LepR Alexa Fluor 647 (BD, 564376, clone 52263, 1:30), <https://www.bdbiosciences.com/en-eu/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/alexa-fluor-647-mouse-anti-human-leptin-receptor-cd295.564376>
 anti-MPO (abcam ab25989, clone 2C7, 1:250), <https://www.abcam.com/products/primary-antibodies/myeloperoxidase-antibody-2c7-ab25989.html>; used for IF of human neutrophils e.g. in Neubert et al., Nat. Communications, 2018.
 anti-Nestin (R&D Systems MAB1259, clone 196908, 1:20), https://www.rndsystems.com/products/human-nestin-antibody-196908_mab1259
 anti-NGFR/CD271 (Sigma HPA004765, 1:500), <https://www.sigmaaldrich.com/DE/de/product/sigma/hpa004765>
 anti-PDGFR β (Cell Signaling 3169S, clone 28E1, 1:100), <https://www.cellsignal.com/products/primary-antibodies/pdgf-receptor-b-28e1-rabbit-mab/3169>
 anti-PRRX1 (Sigma, ZRB2165, 1:50), <https://www.sigmaaldrich.com/DE/de/product/sigma/zrb2165>
 anti-RUNX1/AML-1 (Cell Signaling 4336T, clone D33G6, 1:200), <https://www.cellsignal.com/products/primary-antibodies/aml1-d33g6-xp-rabbit-mab/4336>
 anti S100A8/A9 (abcam ab17050, clone 27E10, 1:200), <https://www.abcam.com/products/primary-antibodies/s100a8--s100a9-antibody-27e10-ab17050.html>;
 anti-SMA (abcam ab5694, 1:200), <https://www.abcam.com/products/primary-antibodies/alpha-smooth-muscle-actin-antibody-ab5694.html>; used for IF in Wimmer et al., Nature, 2019

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

The human fibroblast-derived iPSC cell line HMGU1 (iPSC#1) was provided by the iPSC Core Facility, Institute of Stem Cell Research, Helmholtz Center Munich. The VPS45 mutant (Thr224Asn) was generated from the HMGU1 iPSC cell line (iPSC#1) and has been described previously (Frey et al., Blood, 2021; PMID: 33512427).
 The human renal epithelial cell-derived iPSC cell lines 29B5 (iPSC#2, male) and 12C2 (iPSC#5, female) were provided by the lab of W. Enard, Anthropology and Human Genomics, Faculty of Biology, Ludwig-Maximilians-University Munich and generated from urine samples as previously described (Geuder et al., Sci Rep, 2021, PMID: 33568724).
 The human PBMC-derived iPSC cell line SCTi003-A (iPSC#3, female) was purchased from STEMCELL Technologies (cat. no. 200-0511). The human fibroblast-derived iPSC cell line WTC-11 (iPSC#4, male) was purchased via the Coriell Institute (cat. no. GM25256) from the NIGMS Human Genetic Cell Repository.
 The mouse MS5 cell line was purchased from DMSZ, German Collection of Microorganisms and Cell Cultures GmbH (cat. no. ACC441).

Authentication

Cell lines were not authenticated.

Mycoplasma contamination

The cell lines used in this study were regularly tested negative for mycoplasma. Testing was performed every three weeks.

Commonly misidentified lines (See [ICLAC](#) register)

The cell lines used in this study are not listed in the ICLAC database of commonly misidentified cell lines.

Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals	8-12 week old male and female NSG mice (Charles River) were used for kidney capsule transplantation experiments. 3-4 week old male and female NSG-HLA-DQ8 mice (Jackson Laboratory) were used for HSPC transplantation experiments. Mice were housed under specific pathogen-free conditions in a 12 h light/dark cycle, at 20-22°C temperature, 45-60% humidity and food and water ad libitum.
Wild animals	No wild animals were used in this study.
Reporting on sex	Female and male mice were equally used in this study.
Field-collected samples	No field-collected samples were used in this study.
Ethics oversight	All mice were bred, maintained, examined, and euthanized in accordance with institutional animal care guidelines and ethical animal license protocols approved by the legal authorities. The kidney xenotransplantations were carried out under the animal license number 2022-0.429.375 according to Austrian legislation and approved by the Federal Ministry of Education, Science, and Research of Austria. HSPC xenotransplantations were approved by the Government of Upper Bavaria (Regierung von Oberbayern).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that:

- ☒ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☒ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☒ All plots are contour plots with outliers or pseudocolor plots.
- ☒ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	<p>BMOs were collected and washed once with PBS. Then, organoids were enzymatically dissociated into single cells with 3U/ml Dispase II (Gibco), 2U/ml Liberase (Roche) and 100U DNase (STEMCELL Technologies) in PBS for 25 min at 37°C. During the incubation period, organoids were mechanically disrupted after 10, 20 and 25 minutes by vigorous pipetting using a P1000 and P200 pipette. After 25 minutes, the dissociation reaction was stopped, and single cells were washed with PBS/2%FBS and collected at 300g for 5 minutes. Cells were resuspended in PBS/2%FBS strained through a 70 µm mesh, counted and incubated for 7 minutes with Fc block (Human True Stain FcX, Biolegend) and subsequently stained with the antibodies listed above and in Supp. Table 1.</p> <p>NSG mice with successful kidney transplants were euthanized and the femur and tibia were harvested. The intact bones were sterilized in 70% EtOH for 60 seconds before the bones were crushed in PBS. The bone marrow was extracted from the crushed bones and passed through a filter. Following filtering, red blood cells were lysed with the BD Pharm Lyse kit (BD Biosciences, 555899) according to the manufacturer's instruction. Properly lysed bone marrow cells were subsequently stained with a mix of eBioscience Fixable Viability Dye eFluor 780 (Invitrogen, 65-0865-14) and CD16/CD32 Fc blocking antibody (BD Biosciences, 553141) in PBS for 20 min at 4°C in the dark. After the first stain, cells were washed with FACS buffer and subsequently stained with antibodies listed in Supp. Table 1.</p> <p>NSG-HLA-DQ8 mice were euthanized 10 weeks and 12 weeks after the transplantation. Bone marrow was harvested by flushing bones with PBS/2%FBS. Blood and bone marrow were stained with antibodies listed in Supp. Table 1 and red blood cells were lysed with the BD FACS Lysing solution (BD Biosciences, 349202). Following two washes with PBS/2%FBS blood and bone marrow cells were filtered through a 35µm strainer cap before analysis.</p> <p>ATOs were submerged in staining buffer (PBS/2% FBS/2mM EDTA), mechanically disintegrated by gentle pipetting and passed through a 50 µm strainer. Cells were subsequently stained with antibodies listed in Supp. Table 1.</p>
Instrument	For Data collection a BD Fortessa LSR flow cytometer (BD Bioscience) was used. Sorting was conducted on a BD FACS Aria cell sorter (BD Biosciences).
Software	FACS DIVA software (BD) v9.0.1 was used to collect flow cytometry data. Flow cytometry data were analysed in FlowJo v10.
Cell population abundance	Post-sort analysis of BMO-derived sorted cells showed a purity of >95%.
Gating strategy	For flow cytometry analysis or sorting, cells were initially gated by FSC-A vs SSC-A for the exclusion of debris. For single cells, samples were further gated by FSC-A vs FSC-H or SSC-A vs SSC-H. Dead cells were excluded by a fixable viability stain. For further gating see detailed gating strategies shown in Ext. Data Fig. 1a, Ext. Data Fig. 5c,e, Fig. 3a, Supp. Fig. 1a, Supp. Fig. 5g, Supp. Fig. 6a, Supp. Fig. 9e-h. Gates were drawn according to FMO controls as indicated in Supp. Fig. 1a, Supp. Fig. 6b.

- ☒ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.